

Recent advances in antiemetics: new formulations of 5HT₃-receptor antagonists

James Gilmore¹
Steven D'Amato²
Niesha Griffith³
Lee Schwartzberg^{4,5}

¹Clinical Services, Georgia Cancer Specialists, Atlanta, GA, USA;

²Department of Clinical Pharmacy Services, New England Cancer Specialists, Scarborough, ME, USA;

³West Virginia University Medicine, Morgantown, WV, USA; ⁴West Cancer Center, ⁵Division of Hematology/Oncology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA

Purpose: To discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT₃)-receptor antagonists (RAs).

Summary: CINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24–120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT₃ RA, neurokinin 1 [NK₁] RA, dexamethasone, and olanzapine). For some MEC regimens, a three-drug regimen (5HT₃ RA, NK₁ RA, and dexamethasone) is recommended. While 5HT₃ RAs have dramatically improved CINV in the acute phase (0–24 hours after chemotherapy), their efficacy declines in the delayed phase. Newer formulations have been developed to extend 5HT₃-RA efficacy into the delayed phase. Granisetron extended-release subcutaneous (GERSC), the most recently approved 5HT₃ RA, provides slow, controlled release of therapeutic granisetron concentrations for ≥5 days. GERSC is included in the NCCN and ASCO guidelines for MEC and HEC, with NCCN-preferred status for MEC in the absence of an NK₁ RA. Efficacy and safety of 5HT₃ RAs in the context of guideline-recommended antiemetic therapy are reviewed.

Conclusion: Recent updates in antiemetic guidelines and the development of newer antiemetics should help mitigate CINV, this dreaded side effect of chemotherapy. GERSC, the most recently approved 5HT₃-RA formulation, is indicated for use with other antiemetics to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of MEC and anthracycline–cyclophosphamide combination-chemotherapy regimens.

Keywords: chemotherapy-induced nausea and vomiting, serotonin-receptor antagonist, granisetron extended-release subcutaneous, granisetron extended-release injection, granisetron

Plain-language summary

This review article discusses different treatments that are used to prevent nausea and vomiting (NV) experienced by people with cancer who are being treated with chemotherapy: chemotherapy-induced NV (CINV). The article is about chemotherapy treatments that are the most likely to cause NV in people with cancer, called moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Guidelines from major medical organizations on how to prevent CINV are compared, and the problems in preventing CINV are discussed. Different types of drugs used to treat CINV and different combinations of these drugs are described. Even though several types of drugs are available to prevent CINV, many patients with cancer still suffer from NV. The advantages and disadvantages of drugs used to treat CINV are explained, and information about recently approved new drugs and new forms of existing drugs is provided. The article

Correspondence: James Gilmore
Georgia Cancer Specialists, 1835 Savoy
Drive – suite 203, Atlanta, GA 30341,
USA
Tel +1 770 496 9403
Fax +1 770 454 0548
Email james.gilmore@gacancer.com

mainly describes a class of drugs called 5HT₃-receptor antagonists, which are often used to prevent nausea and vomiting. New drugs and new combinations of drugs may help control CINV in people with cancer who are treated with chemotherapy.

Introduction

Chemotherapy-induced nausea and vomiting (CINV) adversely affects patient health,^{1,2} quality of life,^{3,4} and chemotherapy compliance,⁵ and is one of the most dreaded effects of chemotherapy.⁶ This review focuses on current approaches and future directions involving 5-hydroxytryptamine type 3 (5HT₃)-receptor antagonists (RAs) for the management of CINV. Use of 5HT₃ RAs in the prevention of radiotherapy-induced and chemoradiation-induced NV is discussed briefly.

Chemotherapeutics differ in their emetogenicity. In the absence of antiemetic prophylaxis, agents associated with >90% risk of emesis are classified as highly emetogenic chemotherapy (HEC) and those associated with 30%–90% risk of emesis classified as moderately emetogenic chemotherapy (MEC).^{7–9} Several oral targeted anticancer therapies, such as crizotinib, lenvatinib, olaparib, and panobinostat, are also recognized as being highly or moderately emetogenic.⁷ The emetogenicity of combination regimens is determined by identifying the most emetogenic agent in the combination, then assessing the relative contribution of the other agents.^{7,8} This review discusses treatment options for the prevention of CINV associated with MEC and HEC, as these are the most challenging settings; it does not discuss management of CINV associated with agents that have low-to-minimal emetogenicity.

In clinical trials, measurement of antiemetic efficacy covers a range of end points, involving emesis, nausea, and assessments of rescue medication use for breakthrough CINV (ie, CINV occurring despite the use of prophylactic antiemetics). A commonly used end point is complete response (CR; no emesis and no rescue medication use) during the acute phase (first 24 hours), delayed phase (>24–120 hours), and overall phase (0–120 hours) following chemotherapy administration. End points that also specifically involve nausea include complete control (CC; CR and only mild nausea), total response (CR and no nausea), and no nausea or no significant nausea (typically measured as <25 mm on a 100 mm visual analogue scale).

Despite considerable advances in antiemetics over the past 20 years, beginning with the introduction of the 5HT₃ RAs, prevention of CINV remains suboptimal. For example, one study in a community hospital setting found that chemotherapy-induced nausea and vomiting was reported in approximately 50% and up to a quarter of patients,

respectively, despite antiemetic prophylaxis.¹⁰ Delayed CINV seems to be less well managed than acute CINV. In a US prospective study, 34% of patients reported experiencing acute CINV, whereas 58% of patients reported experiencing delayed CINV.⁴ Both nausea and emesis appear to be more prevalent during the delayed phase than in the acute phase of CINV.¹ Lack of adequate CINV control has multiple adverse consequences. The negative effects of CINV on patient health and quality of life are well known, including reducing patient daily functioning, increasing patient anxiety and depression, and decreasing the patient's chemotherapy treatment adherence, leading to chemotherapy reductions or delays.^{1,3,5,10–12} In addition, the costs of poorly controlled CINV are considerable. Analysis of data from 2018 working-age patients in a large US employment database with information from 45 large employers and more than 100 health-insurance payers (1997–2002) found that 28% of patients had uncontrolled CINV, and the associated monthly medical costs for these patients were approximately US\$1,300 higher and indirect costs US\$433 higher than for patients whose CINV was well controlled.¹³ Using another database of more than 19,000 patients, 14% of patients had a CINV-associated hospital visit (inpatient, outpatient, or emergency room), and the mean cost per visit was US\$4,043.¹⁴ Therefore, prevention of CINV, especially delayed CINV, is critical in patients receiving chemotherapy, for both economic reasons and patient welfare.

Most 5HT₃-RA trials have focused on emesis control, using CR as a primary end point and nausea-control measures as secondary end points. Although emesis control has improved using new classes of antiemetics, the management of nausea, particularly in the delayed phase following HEC, is difficult. However, recent clinical trial focus has turned toward nausea control and the use of different classes of agents to prevent nausea. In a recent Phase III placebo-controlled trial of the antipsychotic olanzapine plus a three-drug antiemetic regimen (a neurokinin 1 [NK₁] RA plus a 5HT₃ RA plus dexamethasone) in patients receiving HEC, nausea prevention was the primary end point. The proportion of patients with no nausea was significantly higher with the addition of olanzapine across acute, delayed, and overall phases of CINV.¹⁵

Granisetron (Kytril; Roche Laboratories Inc., Nutley, NJ, USA [oral] and Genentech, San Francisco, CA, USA [intravenous]), ondansetron (Zofran; GlaxoSmithKline, Research Triangle, NC, USA), and palonosetron (Aloxi; Eisai, Woodcliff Lake, NJ, USA), are the most commonly used 5HT₃ RAs and the focus of this review. Dolasetron IV (Anzemet; Sanofi-Aventis, Bridgewater, NJ, USA) is no longer approved in the USA to prevent CINV, because of potential cardiac effects. Other first-generation 5HT₃ RAs

include azasetron, ramosetron, and tropisetron; however, they are not commercially available in the USA.^{11,16} This review discusses new therapeutic strategies involving 5HT₃ RAs to improve management of delayed CINV following HEC and challenges associated with nausea prevention.

Antiemetic-guideline recommendations

The goal of CINV prophylaxis is to prevent NV following MEC or HEC across both acute and delayed phases. Because CINV is multifactorial, antiemetic prophylaxis often involves agents targeting neurotransmitters with complementary mechanisms of action, such as 5HT₃ RAs, NK₁ RAs, and the atypical antipsychotic olanzapine. Several antiemesis guidelines for clinical practice are available, based on clinical evidence and expert consensus, from the National Comprehensive Cancer Network (NCCN),⁷ Multinational Association for Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO),^{17,18} and American Society of Clinical Oncology (ASCO; Table 1^{7,17–19}).

However, despite the availability of comprehensive CINV-prevention guidelines and a wide range of antiemetics, guideline adherence remains low. The INSPIRE study, involving 1,295 patients from US community practices, found that guideline-consistent CINV prophylaxis was administered in only 57% of patients.²⁰ Corticosteroids were commonly omitted in the delayed phase in patients receiving HEC, as were NK₁ RAs on day 1 in patients receiving MEC regimens, although NK₁ RAs are not uniformly recommended with MEC in antiemetic guidelines.^{7,17–20} Data from the Pan European Emesis Registry of 991 patients found that guideline-consistent CINV prophylaxis during single-day chemotherapy was administered in only 55% of patients in the acute phase and 46% of patients in the delayed phase, and that guideline-consistent CINV prophylaxis significantly reduced the incidence of CINV compared with guideline-inconsistent prophylaxis.²¹ More recently, in a retrospective analysis of a US claims database, of 1,059 patients receiving MEC or HEC, those who were given a guideline-recommended three-drug antiemetic regimen of an NK₁ RA plus a 5HT₃ RA plus dexamethasone had fewer CINV-related emergency-department visits (9%) than patients receiving a two-drug regimen of a 5HT₃ RA plus dexamethasone (15%) and had fewer CINV-related hospitalizations (4% vs 6%, respectively).²² Poor patient adherence to antiemetic regimens, especially to prescribed oral antiemetics, may also be a barrier to effective CINV control, as reported in a multinational survey of 2,388 health-care providers.⁵ Clearly, patients experiencing NV may be reluctant to take oral

medications, even if they are prescribed to control CINV, and many patients undergoing chemotherapy have oral mucositis, which reduces their ability to swallow.²³

Highly emetogenic chemotherapy

For the prevention of CINV associated with single-day HEC, the NCCN and MASCC/ESMO guidelines are in agreement in recommending a three-drug regimen of a 5HT₃ RA plus an NK₁ RA plus a steroid (typically dexamethasone) on day 1 of chemotherapy, followed by dexamethasone on the subsequent 2 or 3 days, with an oral NK₁ RA on days 2 and 3 only if an oral NK₁ RA is given on day 1 (Table 1). The 2017 ASCO and 2018 NCCN guidelines recommend a four-drug regimen that incorporates olanzapine on day 1, in addition to the three-drug regimen just mentioned above, followed by dexamethasone on days 2 and 3, and an oral NK₁ RA on days 2 and 3 only if an oral NK₁ RA is given on day 1; this is also an option in the NCCN guidelines.^{7,19} The NCCN also recommends olanzapine plus palonosetron and dexamethasone as an alternative option on day 1,⁷ and MASCC/ESMO guidelines recommend olanzapine plus a 5HT₃ RA plus dexamethasone for nausea control, but give a low-grade recommendation for this regimen.^{7,17}

Since 2011, the high emetogenicity of the combination of an anthracycline and cyclophosphamide (AC) has been recognized by the NCCN, ASCO, and MASCC/ESMO. AC-based regimens were reclassified from MEC to HEC in the ASCO antiemesis guidelines, and AC-based chemotherapy for patients with breast cancer has a distinct recommendation for CINV prevention within the HEC category in the MASCC/ESMO guidelines.^{7,17,19} Consequently, the ASCO-recommended antiemetic regimen for AC-based regimens is now the same as that recommended by NCCN guidelines for any HEC regimen: primarily a four-drug combination of a 5HT₃ RA, dexamethasone, an NK₁ RA, and olanzapine on day 1, with olanzapine on days 2–4 and dexamethasone on days 2–4 depending on the NK₁ RA administered on day 1.^{7,19} The MASCC/ESMO guidelines recommend the three-drug regimen for AC-based chemotherapy on day 1 for acute CINV, with aprepitant (if aprepitant was given on day 1) or dexamethasone on days 2 and 3 to prevent delayed CINV. However, if any NK₁ RA was given other than aprepitant on day 1, MASCC/ESMO guidelines state that no other treatment is necessary on subsequent days.¹⁷

Carboplatin

Although carboplatin is classified as moderately emetogenic in MASCC/ESMO and ASCO guidelines,^{17–19} NCCN guidelines

Table I Antiemesis-guideline recommendations for CINV prevention following HEC or MEC

| HEC | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Day 1 | Days 2–4 | Guideline |
| A, B, or C A: NK ₁ RA (aprepitant PO or injectable emulsion ^a ; fosaprepitant IV; netupitant/palonosetron PO ^b ; rolapitant PO ^c) + 5-HT ₃ RA ^{d,e} (dolasetron PO; granisetron SC ^f , PO, IV, or GTDS; ondansetron PO or IV; or palonosetron IV) + steroid (dexamethasone ^g PO or IV) B: Olanzapine PO ^h + 5-HT ₃ RA (palonosetron IV) + steroid (dexamethasone ^g PO or IV) C: NK ₁ RA (aprepitant PO or injectable emulsion ^a ; fosaprepitant IV; netupitant/palonosetron PO ^b ; rolapitant PO ^c) + 5-HT ₃ RA ^{d,e} (dolasetron PO; granisetron SC ^f , PO, IV, or GTDS; ondansetron PO or IV; or palonosetron IV) + steroid (dexamethasone ^g PO or IV) + olanzapine PO ^{h,i,j} | A: Aprepitant PO daily on days 2 and 3 (if aprepitant PO used on day 1) + dexamethasone ^g PO/IV daily on days 2–4 B: Olanzapine PO daily on days 2–4 ^h C: Aprepitant PO daily on days 2 and 3 (if aprepitant PO used on day 1) + dexamethasone ^g PO/IV daily on days 2–4 + olanzapine PO daily on days 2–4 ^h | NCCN v2.2018 ⁷ |
| NK ₁ RA (aprepitant PO, fosaprepitant IV, netupitant PO [as NEPA, including 5HT ₃ RA palonosetron], or rolapitant PO) + 5HT ₃ RA ^k (dolasetron PO; granisetron PO, IV, or GTDS; ondansetron PO or IV; palonosetron PO or IV; tropisetron PO) + steroid (dexamethasone PO or IV) | If aprepitant PO day 1, dexamethasone PO or IV days 2–4 + either aprepitant PO days 2 and 3 or metoclopramide days 2–4; otherwise, dexamethasone PO or IV days 2–4 For patients with breast cancer receiving AC-based HEC, if aprepitant day 1, aprepitant PO days 2 and 3 or dexamethasone days 2 and 3; otherwise, no further treatment if fosaprepitant, netupitant, or rolapitant used day 1 | MASCC/ESMO 2016 ¹⁷ |
| If nausea is an issue, olanzapine + 5HT ₃ RA + dexamethasone | | |
| NK ₁ RA (aprepitant PO, fosaprepitant IV, NEPA, or rolapitant PO) + 5HT ₃ RA ^d (granisetron SC, PO, IV, or GTDS; ondansetron PO or IV; palonosetron PO or IV; dolasetron PO; tropisetron PO or IV; ramosetron IV) + steroid (dexamethasone ^l PO) + olanzapine PO | If aprepitant PO day 1, aprepitant days 2 and 3 Dexamethasone ^l PO or IV days 2–4 (if aprepitant used); day 2, twice daily on days 3 and 4 (if fosaprepitant used); days 2–4 (if NEPA or rolapitant used) For AC-based HEC: if no NK ₁ RA day 1, then dexamethasone PO or IV days 2–4 (if aprepitant, fosaprepitant, or NEPA used) + olanzapine PO days 2–4 | ASCO 2017 ¹⁹ |
| MEC | | |
| Day 1 | Days 2 and 3 | Guideline |
| D, E, or F D: 5HT ₃ RA (dolasetron PO; granisetron SC ^f [preferred], PO, IV, or GTDS; ondansetron PO or IV; or palonosetron IV [preferred]) + steroid (dexamethasone ^g PO or IV) E: Olanzapine PO ^h + 5-HT ₃ RA (palonosetron IV) + steroid (dexamethasone ^g PO or IV) F ⁿ : NK ₁ RA (aprepitant PO or injectable emulsion ^a ; fosaprepitant IV; netupitant/palonosetron PO ^b ; rolapitant PO ^c) + 5-HT ₃ RA ^{d,e} (dolasetron PO; granisetron SC ^f , PO, IV, or GTDS; ondansetron PO or IV; or palonosetron IV) + steroid (dexamethasone ^g PO or IV) | D: Dexamethasone ^g PO/IV daily on days 2 and 3 or 5-HT ₃ RA ^m (granisetron PO or IV, or ondansetron PO or IV or dolasetron PO) E: Olanzapine PO daily on days 2 and 3 ^h F: Aprepitant PO daily on days 2 and 3 (if aprepitant PO used on day 1) ± dexamethasone ^g PO/IV daily on days 2 and 3 | NCCN v2.2018 ⁷ |
| 5HT ₃ RA + dexamethasone ^o (except for carboplatin regimens) | Dexamethasone days 2 and 3 (for patients treated with MEC, which has known potential for delayed emesis, eg, oxaliplatin, doxorubicin, or cyclophosphamide); no routine antiemetic prophylaxis for other chemotherapeutic agents | MASCC/ESMO 2016 ¹⁸ |
| For carboplatin regimens: NK ₁ RA + 5HT ₃ RA + dexamethasone | If aprepitant day 1, aprepitant days 2 and 3 If other NK ₁ RA day 1, no additional antiemetic prophylaxis | |

(Continued)

Table 1 (Continued)

| MEC | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|-------------------------|
| Day 1 | Days 2 and 3 | Guideline |
| 5HT ₃ RA (dolasetron PO; granisetron SC, PO, IV, or GTDS; ondansetron IV or PO; or palonosetron IV or PO) + dexamethasone (IV or PO) (except for carboplatin regimens) For carboplatin regimens ^b : 5HT ₃ RA + dexamethasone | Dexamethasone PO or IV days 2 and 3 | ASCO 2017 ¹⁹ |

Notes: ^aAprepitant injectable emulsion is a unique formulation of aprepitant and is not interchangeable with the intravenous formulation of fosaprepitant; ^bAvailable as a fixed combination product only; ^cRolapitant has an extended half-life and should not be administered at less than 2-week intervals; ^dIf netupitant/palonosetron fixed combination product used, no further 5-HT₃ RA is required; ^eWhen used in combination with an NK₁ antagonist, there is no preferred 5-HT₃ RA; ^fGranisetron extended-release injection is a unique formulation of granisetron using a polymer-based drug delivery system. This formulation is specifically intended for subcutaneous administration and is not interchangeable with the intravenous formulation. Granisetron extended-release injection has an extended half-life and should not be administered at less than 1-week intervals; ^gEmerging data in clinical practice suggest dexamethasone doses may be individualized. Higher doses may be considered, especially when an NK₁ RA is not given concomitantly. Lower doses, given for shorter durations, or even elimination of dexamethasone on subsequent days (for delayed nausea and emesis prevention) may be acceptable for non-cisplatin regimens based on patient characteristics; ^hConsider 5 mg dose for elderly or over-sedated patients; ⁱConsider escalating to this option (C) when emesis induced by highly emetogenic cisplatin-based chemotherapy using an olanzapine regimen (B, E) or an NK₁ antagonist-containing regimen (A, B, D, or F); ^jCombination of olanzapine, aprepitant, or fosaprepitant, any 5-HT₃ RA, and dexamethasone was studied in patients receiving cisplatin or AC; ^kFor patients receiving AC-based HEC, if NK₁ RA is not available, palonosetron is the preferred agent; ^lIf NK₁ RA is not given day 1, higher dexamethasone dose is recommended days 1–4; ^mNo further therapy required if palonosetron, granisetron extended-release injection, or granisetron transdermal patch given on day 1; ⁿNK₁ RA should be added (to dexamethasone and a 5-HT₃ RA regimen for select patients with additional risk factors or previous treatment failure with a steroid + 5HT₃ RA alone; ^oDexamethasone only in patients receiving MEC with a known potential for delayed emesis; ^pIf carboplatin area under the concentration-time curve (AUC) is ≥4 mg/mL/min, add NK₁ RA.

Abbreviations: 5HT₃, 5-hydroxytryptamine type 3; AC, anthracycline–cyclophosphamide; ASCO, American Society of Clinical Oncology; CINV, chemotherapy-induced nausea and vomiting; ESMO, European Society of Medical Oncology; GTDS, granisetron transdermal system; HEC, highly emetogenic chemotherapy; IV, intravenously; MASCC, Multinational Association for Supportive Care in Cancer; MEC, moderately emetogenic chemotherapy; NCCN, National Comprehensive Cancer Network; NEPA, fixed-dose netupitant + palonosetron; NK₁, neurokinin 1; PO, per os (orally); RA, receptor antagonist; SC, subcutaneously.

note that carboplatin may be highly emetogenic in some patients, depending on dose (ie, if the carboplatin area under the concentration–time curve [AUC] is ≥4 mg/mL/min), and ASCO recommends an adjusted antiemetic regimen for patients receiving carboplatin with an area under the curve ≥4 mg/mL/min.^{7,19} For patients receiving carboplatin, MASCC/ESMO guidelines recommend a three-drug antiemetic regimen of a 5HT₃ RA plus an NK₁ RA plus dexamethasone, similar to the regimen recommended for patients receiving HEC, with aprepitant on days 2 and 3 if given on day 1.¹⁷ In a retrospective analysis of 1,059 patients in a US claims database, 73% of those treated with AC (classified as HEC) and 56% treated with cisplatin (HEC) received an antiemetic regimen containing an NK₁ RA compared with 23% treated with carboplatin. However, health-care-resource utilization (eg, emergency-room visits, hospitalization) was lower in patients whose antiemetic regimen included an NK₁ RA, suggesting that a three-drug antiemetic regimen may be more effective in preventing CINV in patients receiving carboplatin.²²

Moderately emetogenic chemotherapy

For the prevention of CINV associated with single-day MEC, all three guidelines are in agreement in recommending a two-drug regimen of a 5HT₃ RA plus dexamethasone on day 1 and dexamethasone on days 2 and 3 (with some exceptions), although ASCO and MASCC/ESMO guidelines have separate recommendations for patients receiving carboplatin (Table 1).^{7,17–19} The NCCN guidelines also recommend this two-drug

regimen plus an NK₁ RA on day 1 or a three-drug combination of olanzapine, palonosetron, and dexamethasone on day 1.⁷ If the 5HT₃ RA palonosetron, extended-release (ER) granisetron transdermal delivery system (GTDS; Sancuso, ProStrakan, Bridgewater, NJ, USA), or granisetron ER subcutaneous (GERSC; Sustol, Heron Therapeutics, Redwood City, CA, USA) is given on day 1 with dexamethasone, NCCN guidelines state that no further antiemetic therapy is necessary on days 2 and 3.⁷ Details of recommended prophylaxis on days 2 and 3 by all guidelines are shown in Table 1. For MEC, NCCN guidelines list palonosetron and GERSC as preferred 5HT₃ RAs in the absence of an NK₁ RA.⁷

Multiday chemotherapy

For multiday chemotherapy, treatment guidelines are less definitive, in part because there is a lack of evidence to support recommendations in this setting. ASCO guidelines suggest using an antiemetic agent appropriate for the emetogenic risk of the chemotherapeutic agent administered on each day and for 2 days after completion of the chemotherapy regimen, and suggest that the ER agents GTDS or GERSC may be preferable to a daily 5HT₃ RA. For patients receiving multiday cisplatin regimens, the three-drug combination of an NK₁ RA, 5HT₃ RA, and dexamethasone is recommended.¹⁹ The NCCN guidelines propose taking several factors into account when determining the appropriate antiemetic regimen, including route of administration, duration of action, and dosage regimen of the antiemetic(s); administration in an inpatient or

outpatient setting; patient adherence to a regimen; and individual patient risk factors. Several general principles are proposed for each type of antiemetic agent. A 5HT₃ RA should be used before each dose of MEC or HEC, and the need for subsequent doses should be based on the antiemetic agent and route of administration. Dexamethasone is recommended for each day of chemotherapy, continuing for 2–3 days afterward for HEC or MEC regimens known to have a higher risk of causing delayed emesis, but dexamethasone administration only on day 1 is an option for patients receiving MEC or noncisplatin HEC who have few CINV risk factors. An NK₁ RA may be used with MEC or HEC regimens that have a significant risk of causing delayed CINV, but there are limited data on the use of NK₁ RAs over multiple days.⁷ The most recent updates to the MASCC/ESMO guidelines do not offer specific recommendations for antiemetics to prevent CINV associated with multiday HEC or MEC chemotherapy.^{17,18}

Breakthrough CINV

For breakthrough CINV (ie, CINV occurring despite the use of guideline-recommended prophylactic antiemetics), ASCO and NCCN guidelines suggest adding an antiemetic agent with a different mechanism of action to that of the antiemetic(s) used during the previous chemotherapy cycle. Olanzapine may be added if it was not part of the initial antiemetic regimen, and other dopamine antagonists (eg, metoclopramide, phenothiazines) may also be considered.^{7,19} Multiple concurrent antiemetics may be required and administered continuously, rather than as needed. If a combination of a 5HT₃ RA and dexamethasone with or without an NK₁ RA has previously been used, other options of different classes include olanzapine, benzodiazepine, or metoclopramide.^{7,19} The use of 5HT₃ RAs in the breakthrough setting is based on their efficacy as prophylactic antiemetics, as there are no published data from prospective Phase III clinical trials on the use of 5HT₃ RAs to treat breakthrough CINV. The most recent updates to the MASCC/ESMO guidelines have no specific recommendations for the prevention of breakthrough CINV associated with HEC or MEC.^{17,18}

Benefits and limitations of 5HT₃-RA formulations

The introduction of 5HT₃ RAs dramatically improved the prevention of CINV, particularly in the acute phase.²⁴ Granisetron is a potent and highly selective 5HT₃ RA with little or no affinity for other serotonin receptors or for dopaminergic, adrenergic, benzodiazepine, histaminic, or opioid receptors.²⁵ In contrast, in addition to binding with 5HT₃

receptors, ondansetron binds with low affinity to 5HT_{1B}, 5HT_{1C}, α_1 -adrenergic, and μ -opioid receptors.²⁶ Ondansetron is available for intravenous (IV) or oral administration only, whereas granisetron is available in a wide range of formulations (Table 2^{25,27–37}). Dolasetron is only available in the oral formulation in the USA for CINV prevention (Table 2) due to the potential cardiac adverse events (AEs) observed with the IV formulation. Formulations of 5HT₃ RAs may affect their utility. Injectable forms have an adherence advantage, whereas compliance with oral antiemetics may be suboptimal because of difficulty ingesting pills, especially for patients with head and neck cancer or those afraid to swallow pills for fear of inducing further emesis.^{38,39}

Extending the efficacy of 5HT₃ RAs into the delayed phase: palonosetron

Palonosetron, a potent and selective 5HT₃ RA, is a second-generation agent with a half-life ($t_{1/2}$) that is longer (~40 hours)⁴⁰ than first-generation agents (Table 2). Additionally, in vitro research has suggested that palonosetron causes 5HT₃-receptor internalization, leading to prolonged inhibition of 5HT₃ RAs.⁴¹ These properties ($t_{1/2}$, binding affinity, and receptor internalization) of palonosetron are believed to form the basis of its pharmacologic activity in the acute and delayed CINV phases.^{26,41–43} However, direct evidence linking biochemical properties of palonosetron with its clinical efficacy is lacking. Notably, palonosetron IV is indicated for CINV prevention in both acute and delayed phases following MEC, but only in the acute phase following HEC.³⁴ In the USA, palonosetron is available only for IV administration.³⁴ At the time of its approval in the USA, palonosetron had not been investigated in combination with an NK₁ RA.

In 2014, the oral fixed-dose combination of the NK₁ RA netupitant 300 mg and palonosetron 0.5 mg (NEPA; Akynzeo, Helsinn Therapeutics Inc, Iselin, NJ, USA) became available for CINV prevention in both acute and delayed phases in patients treated with MEC or HEC.³⁶ Approval was based on three clinical trials in patients receiving HEC, MEC, and repeated cycles of chemotherapy.^{37,44,45} In single-cycle trials in patients receiving MEC or HEC, NEPA plus dexamethasone was significantly superior to the comparator regimen across the delayed and overall CINV phases in terms of CR.^{44,45} However, in these trials, NEPA plus dexamethasone was compared with a two-drug regimen of oral palonosetron plus dexamethasone, not the three-drug regimen recommended by all guidelines for patients receiving HEC and by some guidelines for patients receiving MEC.^{7,17–19} Over multiple cycles, NEPA plus dexamethasone had similar CR rates to

Table 2 Characteristics of 5HT₃-RA formulations

| Drug | Route of administration | Mean plasma $t_{1/2}$ (hours) | Approved adult dose and administration | Year of initial US approval; indication in adults for prevention of CINV |
|----------------------------------|-----------------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Dolasetron | PO ²⁷ | 7.3 ($t_{1/2}$ of hydrodolasetron, a dolasetron metabolite) | 100 mg within 1 hour before chemotherapy | 1997; associated with MEC, including initial and repeat course |
| Granisetron | IV ²⁵ | 9 (mean plasma $t_{1/2}$) | Single dose of 3 mg granisetron diluted in 20–50 mL infusion fluid given over 5 minutes, beginning within 30 minutes before chemotherapy start | 1993; induced by cytotoxic chemotherapy |
| Granisetron | PO ²⁸ | 6.23 (terminal phase $t_{1/2}$, in healthy volunteers) | 2 mg once daily (two 1 mg tablets or 10 mL oral solution) up to 1 hour before chemotherapy start or 1 mg twice daily, with first dose (1 mg tablet or 5 mL oral solution) given up to 1 hour before chemotherapy start and second dose (tablet or 5 mL oral solution) 12 hours after first dose | 2001; associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin |
| Granisetron | Extended-release SC ²⁹ | 26.15 (750 mg), 28.8 (500 mg) ³⁰ | Single SC injection in upper arm or abdomen at least 30 minutes before chemotherapy start | 2016; acute and delayed NV associated with initial and repeat courses of cancer chemotherapy, including but not limited to HEC |
| Granisetron | TD ³¹ | NA | Patch is 52 cm ² and contains 34.3 mg granisetron, delivered at 3.1 mg/24 hours; single transdermal patch applied to upper outer arm ≥24 hours (to maximum 48 hours) before chemotherapy; can wear patch up to 7 days, depending on chemotherapy duration | 2008; in patients receiving MEC and/or HEC for up to 5 consecutive days |
| Ondansetron | IV ³² | 3.5–5.5 (depending on age) | Three 0.15 mg/kg doses to maximum 16 mg/dose; first dose infused over 15 minutes, beginning 30 minutes before chemotherapy start; subsequent doses 4 and 8 hours after first dose | 1991; associated with initial and repeat courses of emetogenic cancer chemotherapy |
| Ondansetron | PO ³³ | 3.1–6.2 (mean elimination $t_{1/2}$ for 8 mg dose; depending on age) | HEC: 24 mg as three 8 mg tablets 30 minutes before start of single-day HEC, including cisplatin ≥50 mg/m ² MEC: one 8 mg tablet or 10 mL oral solution twice a day; first dose 30 minutes before chemotherapy; subsequent dose 8 hours after first dose; for 1–2 days after completion of chemotherapy, one 8 mg tablet or 10 mL oral solution twice a day (every 12 hours) | 1992; associated with: • HEC, including cisplatin ≥50 mg/m ² • Initial and repeat courses of MEC |
| Palonosetron | IV ³⁴ | 40 ³⁵ | 0.25 mg once, infused over 30 seconds beginning ~30 minutes before chemotherapy start | 2003; acute and delayed NV associated with initial and repeat MEC; acute NV associated with initial and repeat HEC |
| Palonosetron + netupitant (NEPA) | PO ³⁶ | 90 ³⁷ | One NEPA capsule (300 mg netupitant/0.5 mg palonosetron) ~1 hour before chemotherapy start, with or without food | 2014; acute and delayed NV associated with initial and repeat cancer chemotherapy, including but not limited to HEC |

Abbreviations: 5HT₃, 5-hydroxytryptamine type 3; CINV, chemotherapy-induced nausea and vomiting; HEC, highly emetogenic chemotherapy; IV, intravenously; MEC, moderately emetogenic chemotherapy; NA, not available; NEPA, fixed-dose netupitant + palonosetron; NV, nausea and vomiting; PO, per os (orally); SC, subcutaneously; RA, receptor antagonist; $t_{1/2}$, half-life; TD, transdermal.

a three-drug regimen of aprepitant, palonosetron, and dexamethasone, but a small numerical advantage in the delayed and overall phases.³⁷ In clinical trials, the NK₁ RA provided additional control of delayed CINV in combination with a 5HT₃ RA, suggesting that the NK₁ RA is providing the ben-

efit in the delayed phase.^{46,47} In fact, the NEPA prescribing information states that palonosetron prevents CINV in the acute phase and netupitant prevents CINV in the acute and delayed phases.³⁶ Since NEPA provides an NK₁ RA and a 5HT₃ RA as a single oral dose, it has the potential to improve

the prevention of delayed CINV and improve adherence to guidelines for CINV prevention following HEC, which recommend combined use of NK₁ RA and 5HT₃ RA plus a corticosteroid.⁴⁸ However, oral administration of NEPA may pose a challenge to some patients, as discussed earlier.

Palonosetron and its place in antiemetic treatment guidelines

Antiemesis guidelines recommend palonosetron as a preferred 5HT₃ RA in some settings. In patients with breast cancer receiving AC-based chemotherapy (ie, a HEC regimen), a three-drug regimen of a 5HT₃ RA, dexamethasone, and an NK₁ RA is recommended by the MASCC/ESMO guidelines, but palonosetron is stated as the preferred 5HT₃ RA if an NK₁ RA is not available.¹⁷ These recommendations were based on the results of Phase III trials of palonosetron in patients receiving HEC (Table 3^{49–60}).^{49,50} In patients receiving MEC or multiday chemotherapy, either palonosetron or GERSC is recommended in NCCN guidelines as a preferred 5HT₃ RA in combination with dexamethasone for CINV prevention (ie, when no NK₁ RA is given).⁷ In a recent trial in 341 patients with breast cancer receiving AC-based chemotherapy (reported as an abstract), palonosetron failed to show superiority over granisetron IV (CR 62.3% vs 60.4%, $P=0.8$) in the delayed phase, when each agent was combined with fosaprepitant and dexamethasone.⁶¹ Recently, a double-blind, randomized study comparing a three-drug palonosetron regimen with a three-drug granisetron regimen in patients receiving AC-based HEC showed no significant difference between study arms in terms of delayed-phase CR, despite again using the 0.75 mg palonosetron dose.⁶²

The NCCN guidelines considered two Phase III trials in the MEC setting to support palonosetron as a preferred 5HT₃ RA in combination with dexamethasone to prevent CINV associated with MEC.^{63,64} However, one study in patients receiving MEC reported that palonosetron IV was noninferior to dolasetron IV, which is no longer approved by the US Food and Drug Administration (FDA) for CINV prevention because of associated cardiac adverse effects (Table 4^{45,59,60,63–73}).^{63,74} The other study demonstrated superior CR in acute and delayed CINV phases of single-dose palonosetron 0.25 mg IV compared with single-dose ondansetron 32 mg IV in patients receiving MEC (Table 4).⁶⁴ However, this study did not use the recommended combination of ondansetron with dexamethasone. In a subsequent Phase III trial in patients receiving HEC, palonosetron 0.25 mg IV was noninferior to a first-generation 5HT₃ RA (ondansetron 32 mg IV) in acute, delayed, and overall phases. Superiority of palonosetron to

ondansetron was shown only in a post hoc analysis, where CR with palonosetron was significantly higher in the delayed and overall phases compared with ondansetron when both agents were administered with dexamethasone.⁴⁹

As such, the evidence to support the preference for palonosetron in CINV prevention in these settings has been questioned, and it has been suggested that there are insufficient data to support this designation.^{75,76} Phase III trials evaluated single-dose palonosetron compared with single-dose dolasetron or ondansetron, both of which have shorter $t_{1/2}$ than palonosetron (Table 2), so would be expected to be less effective at controlling CINV beyond day 1 of chemotherapy. Meta-analyses of CINV trials have been used to support the choice of palonosetron as the preferred 5HT₃ RA in CINV prevention.^{77,78} However, such analyses may result in pooling data from trials with significant differences in study populations and dexamethasone usage, so their conclusions require validation in prospective, randomized trials.

Extending the efficacy of 5HT₃ RAs into the delayed phase: granisetron

The short $t_{1/2}$ of the first-generation 5HT₃ RAs (Table 2), such as granisetron, has limited their use in CINV prevention, especially for the delayed phase. Currently, two ER formulations of granisetron are available: GTDS and GERSC (previously APF530). The GTDS patch, which is 52 cm² in size, provides exposure similar to that of 2 mg oral granisetron. However, in contrast to oral granisetron, where maximum plasma concentration (C_{max}) is reached 2 hours after administration, drug exposure with GTDS is slower, with C_{max} reached 48 hours after patch application and granisetron exposure continuing over 5 days (Figure 1^{29–31,79}).⁷⁹ Therefore, GTDS is a convenient option for CINV prevention, because it reduces pill burden for patients, particularly those who have difficulty in swallowing oral medication.²³ However, GTDS has potential drawbacks, including patch detachment,^{80–82} which may result in a lack of antiemetic efficacy, and the need for patch application 24–48 hours prior to chemotherapy, which may result in unnecessary exposure to antiemetic if the patient does not proceed with their next round of chemotherapy.⁸³

GERSC was developed as a long-acting formulation to provide prolonged 5HT₃-RA action through sustained granisetron release, and was recently FDA-approved for use in adults in combination with other antiemetics for prevention of acute and delayed NV associated with initial and repeat courses of MEC or AC-combination chemotherapy regimens.²⁹ Extended granisetron release is achieved through Biochronomer technology (Figure 2) using a viscous,

Table 3 Results of Phase III clinical trials evaluating antiemetic efficacy in CINV prevention following HEC

| Study | Antiemetic treatment and DEX dose | Patient demographics ^a | Primary end-point result | Secondary end-point result |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Four-drug vs four-drug regimen | | | | |
| Navari et al 2013 ⁵¹ | (OLN vs metoclopramide [MTCPr]) + (PALO + FOS + DEX) Day 1: PALO 0.25 mg IV + FOS 150 mg IV, DEX 12 mg IV Days 2–4: DEX 8 mg PO qd Days 2–5: OLN 10 mg PO qd or MTCPr 10 mg PO tid | N=276 Median age 61–63 years, female 28%–30%, chemotherapy-naïve 100% | OLN vs MTCPr Patients with no emesis in 72 hours after starting treatment 68% vs 23%, P<0.01 | OLN vs MTCPr Patients with no nausea in 72 hours after starting treatment 68% vs 23%, P<0.01 |
| Three-drug vs three-drug regimen | | | | |
| Grunberg et al 2011 ⁵² | APR + OND + DEX vs FOS + OND + DEX FOS regimen Day 1: FOS 150 mg IV, OND 32 mg IV, DEX 12 mg PO Day 2: DEX 8 mg PO Days 3–4: DEX 8 mg bid APR regimen Day 1: APR 125 mg PO, OND 32 mg IV, DEX 12 mg PO Days 2–3: APR 80 mg PO, DEX 8 mg PO Day 4: DEX 8 mg PO | N=2,322 Median age 56–57 years, female 36%–37% | APR vs FOS CR overall phase: 71.9%, 95% CI 69.1%–74.5% vs 72.3%, 95% CI 69.6%–74.9% | APR vs FOS CR delayed phase: 74.3%, 95% CI 71.6%–76.9% vs 74.2%, 95% CI 71.6%–76.8% No emesis overall phase: 72.9%, 95% CI 70.2%–75.5% vs 74.6%, 95% CI 71.9%–77.1% |
| Navari et al 2011 ⁵³ | OLN + PALO + DEX vs APR + PALO + DEX Day 1: OLN 10 mg PO + PALO 0.25 mg IV + DEX 20 mg IV Days 2–4: OLN 10 mg/d PO (OPD) or Day 1: APR 125 mg PO + PALO 0.25 mg IV + DEX 12 mg IV Days 2–4: APR 80 mg PO + DEX 4 mg bid (APD) | N=247 Median age: 61–63 years, female 81%–83%, chemotherapy-naïve 100% | OLN vs APR CR overall phase: 77% vs 73%; P<0.05 CR delayed phase: 77% vs 73%, P>0.05 No nausea Acute phase: 87% vs 87%, P>0.05 Delayed phase: 69% vs 38%; P<0.01 Overall phase: 69% vs 38%, P<0.01 | OLN vs APR CR acute phase: 97% vs 87%, P>0.05 CR delayed phase: 77% vs 73%, P>0.05 No nausea Acute phase: 87% vs 87%, P>0.05 Delayed phase: 69% vs 38%; P<0.01 Overall phase: 69% vs 38%, P<0.01 |
| Schnadig et al 2016 ⁵⁴ | GERSC + FOS + DEX vs OND + FOS + DEX Three-drug regimen GERSC 10 mg SC (GRA 10 mg), OND placebo IV or OND 0.15 mg/kg IV, GERSC placebo SC, each with FOS 150 mg IV day 1 Day 1: DEX 12 mg IV Day 2: DEX 8 mg PO qd Days 3–4: DEX 8 mg PO bid | N=942 Mean age 56 years, female 80%–83%, white 82%, current alcohol use 37%–38%, smokers 16% | GERSC vs OND CR delayed phase: 64.7% vs 56.6%, P=0.014 | GERSC vs OND CR overall phase: 58.4% vs 52.9%, P=0.092, P=0.275* CC delayed phase: 60.7% vs 53.1%, P=0.088, P=0.088* CC overall phase: 54.7% vs 49.6%, P=0.123, P=0.247* Rate of no emetic episodes: 82.2% vs 79.2%, P=0.254, P=0.254* *Hochberg-adjusted |

(Continued)

Table 3 (Continued)

| Study | Antiemetic treatment and DEX dose | Patient demographics ^a | Primary end-point result | Secondary end-point result |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Three-drug vs two-drug regimen | | | | |
| Hesketh et al 2003 ⁵⁵ | <p>APR + OND + DEX vs placebo + OND + DEX</p> <p>Standard-therapy group</p> <p>Day 1: OND 32 mg IV + DEX 20 mg PO</p> <p>Days 2–4: DEX 8 mg bid</p> <p>APR group</p> <p>Day 1: APR 125 mg PO + OND 32 mg IV + DEX 12 mg PO</p> <p>Days 2–3: APR 80 mg PO + DEX 8 mg PO qd</p> <p>Days 2–4: DEX 8 mg PO qd</p> | <p>N=530</p> <p>Mean age 58–59 years, female 14%, white 34%–35%, no alcoholic drinks/week 22%</p> | <p>CR overall (days 1–5 postcisplatin): APR vs placebo, 72.7% vs 52.3%, $P<0.001$</p> | <p>Secondary and exploratory end points</p> <p>CR acute phase: 89.2% vs 78.1%, $P<0.001$</p> <p>CR delayed phase: 75.4% vs 55.8%, $P<0.001$</p> <p>No emesis</p> <p>Acute phase: 90.0% vs 79.3%, $P<0.01$</p> <p>Delayed phase: 80.8% vs 58.8%, $P<0.01$</p> <p>Overall phase: 77.7% vs 55.0%, $P<0.01$</p> <p>No nausea</p> <p>Acute phase: 72.3% vs 69.1%</p> <p>Delayed phase: 51.0% vs 47.7%</p> <p>Overall phase: 47.5% vs 44.2%</p> |
| Poli-Bigelli et al 2003 ⁵⁶ | <p>APR + OND + DEX vs placebo + OND + DEX</p> <p>APR, OND, DEX vs OND, DEX</p> <p>Day 1: OND 32 mg IV + DEX 20 mg</p> <p>Days 2–4: DEX 8 mg bid</p> <p>or</p> <p>Day 1: APR 125 mg PO + OND 32 mg IV + DEX 12 mg PO</p> <p>Days 2–3: APR 80 mg PO + DEX 8 mg PO qd</p> <p>Day 4: DEX 8 mg PO</p> | <p>N=569</p> <p>Mean age 53–54 years, white 28%–31%, female 48%–49%, no alcohol per week 84%–87%</p> | <p>CR overall phase: APR vs placebo, 62.7% vs 43.3%, $P<0.001$</p> | <p>CR acute phase: 82.8% vs 68.4%</p> <p>CR delayed phase: 67.7% vs 46.8%</p> |
| Saito et al 2013 ⁵⁷ | <p>FOS + GRA + DEX vs placebo + GRA + DEX</p> <p>FOS group</p> <p>Day 1: FOS 150 mg, IV, GRA 40 µg/kg, IV, DEX 10 mg IV</p> <p>Day 2: DEX 4 mg IV</p> <p>Day 3: DEX 8 mg IV</p> <p>Control group</p> <p>Day 1: placebo, GRA 40 µg/kg, IV, DEX 20 mg IV</p> <p>Days 2–3: DEX 8 mg IV</p> | <p>N=347</p> <p>Median age 62–63 years, female 26%, no alcohol intake 50%–64%</p> | <p>FOS vs placebo</p> <p>CR overall phase: 64.2% vs 47.3%, $P=0.0015$</p> | <p>FOS vs placebo</p> <p>CR acute phase: 93.6% vs 80.8%, $P<0.005$</p> <p>CR delayed phase: 64.7% vs 48.6%, $P<0.005$</p> |
| Hu et al 2014 ⁵⁸ | <p>APR + GRA + DEX vs placebo + GRA + DEX</p> <p>APR regimen</p> <p>Day 1: APR 125 mg PO, GRA 3 mg IV, DEX 6 mg PO</p> <p>Days 2–3: APR 80 mg PO, DEX 3.75 mg PO</p> <p>Day 4: DEX 3.75 mg PO</p> <p>Standard regimen</p> <p>Day 1: placebo, GRA 3 mg IV, DEX 10.5 mg PO</p> <p>Days 2–4: DEX 7.5 mg PO</p> | <p>N=421</p> <p>Mean age 53–54 years, female 34%, no alcohol use 84%–85%</p> | <p>APR vs placebo</p> <p>CR overall phase: 69.6% vs 57.0%, $P=0.007$</p> | <p>APR vs placebo</p> <p>CR acute phase: 79.4% vs 79.3%, $P=0.9$</p> <p>CR delayed phase: 74.0% vs 59.4%, $P<0.001$</p> |

| Two-drug vs two-drug regimen | | | |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aspro et al 2006 ⁴⁹ | <p>PALO + DEX vs OND + DEX</p> <p>PALO 0.25 or 0.75 mg IV or OND 32 mg IV</p> <p>Day 1: single dose of DEX 20 mg IV allowed at physician discretion but not required, DEX prophylaxis in 67.3% of PALO, 66.5% of OND patients</p> | <p>N=673</p> <p>Mean age, 51–53 years, female 51%–52%, white 51%–63%, no alcohol use 49%–52%, chemotherapy-naïve 58%–60%</p> | <p>PALO vs OND</p> <p>PALO 0.25 mg vs OND</p> <p>CR delayed phase: 45.3% vs 38.9%, P=0.180</p> <p>CR overall phase: 40.8% vs 33%, P=0.095</p> <p>PALO 0.75 mg vs OND</p> <p>CR delayed phase: 48% vs 38.9%, P=0.056</p> <p>CR overall phase: 42.2% vs 33%, P=0.051</p> <p>Subgroup analysis of patients receiving study drug and prophylactic DEX during acute, delayed, and overall phases</p> <p>PALO 0.25 mg vs OND</p> <p>CR acute phase: 64.7% vs 55.8%</p> <p>CR delayed phase: 42.0% vs 28.6%, statistically significant</p> <p>CR overall phase: 40.7% vs 25.2%, statistically significant</p> |
| Saito et al 2009 ⁵⁰ | <p>PALO + DEX vs GRA + DEX</p> <p>PALO 0.75 mg IV or GRA 40 µg/kg IV</p> <p>Day 1: DEX 16 mg IV</p> <p>Days 2–3: DEX 8 mg IV for cisplatin-treated patients or 4 mg PO for AC-treated patients</p> | <p>N=1,143</p> <p>Mean age 58 years, female 58%–59%, all patients from Japan, no alcohol use 42%–43%, chemotherapy-naïve 7%–8%</p> | <p>PALO vs GRA</p> <p>CR overall phase: 51.5% vs 40.4%, P=0.0001</p> <p>CC acute phase: 73.7% vs 72.1%, P=ND</p> <p>CC delayed phase: 53.0% vs 42.4%, P=0.0003</p> <p>CC overall phase: 47.9% vs 38.1%, P=0.0007</p> <ul style="list-style-type: none"> • Number of emetic episodes, time to first emetic episode, and time to first use of rescue medication higher in PALO vs GRA • Time to treatment failure and percentage patients with severe nausea similar within 24 hours, lower in PALO vs GRA (5% vs 1.6%) at 96 hours • Statistically significantly higher number patients in PALO vs GRA with no nausea and no emetic episodes in delayed or overall phases |

(Continued)

Table 3 (Continued)

| Study | Antiemetic treatment and DEX dose | Patient demographics ^a | Primary end-point result | Secondary end-point result |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Raftopoulos et al 2015 ⁵⁹ | <p>GERSC + DEX vs PALO + DEX</p> <p>GERSC 5 mg or 10 mg SC, placebo IV or PALO 0.25 mg IV, placebo SC</p> <p>Day 1: DEX 20 mg IV</p> <p>Days 2–4: DEX 8 mg PO bid</p> | <p>N=1,428</p> <p>Mean age 57–58 years, female 63%–67%, white 58%–62%, chemotherapy-naïve 56–59%</p> | <p>GERSC vs PALO in cycle 1 of HEC</p> <p>GERSC 5 mg SC vs PALO 0.25 mg IV</p> <p>CR acute phase: 77.7% vs 80.7%, <i>P</i>=0.49</p> <p>CR delayed phase: 62.4% vs 64.3%, <i>P</i>=0.70</p> <p>GERSC 10 mg SC vs PALO 0.25 mg IV</p> <p>CR acute phase: 81.3% vs 80.7%, <i>P</i>=0.91</p> <p>CR delayed phase: 67.1% vs 64.3%, <i>P</i>=0.56</p> | <p>GERSC vs PALO</p> <p>CR overall phase, HEC</p> <p>GERSC 5 mg vs PALO 0.25 mg 57.6% vs 60.5%, 95% CI –11.8 to 6.1, <i>P</i>=NA</p> <p>GERSC 10 mg vs PALO 0.25 mg 63.3% vs 60.5%, 95% CI –5.9 to 11.6, <i>P</i>=NA</p> |
| One-drug vs one-drug regimen | | | | |
| Gebbia et al 1994 ⁶⁰ | <p>OND vs GRA</p> <p>Day 1: OND 24 mg IV or GRA 3 mg IV</p> <p>Patients on fractionated chemotherapy</p> <p>Subsequent days: OND 8 mg PO bid or GRA 3 mg IV</p> | <p>N=182</p> <p>Mean age, 59–60 years, female 31%–42%</p> | <p>OND vs GRA</p> <p>CR acute phase: 52% vs 49%, no significant difference</p> <p>CR delayed phase: 39% vs 36%, no significant difference</p> | |

Note: ^aNEPA, APR, and PALO administered 60 minutes prior to chemotherapy administration on day 1.

Abbreviations: AC, anthracycline–cyclophosphamide; APD, aprepitant; palonosetron, dexamethasone; APR, aprepitant; bid, bis in die (twice daily); CC, complete control; CINV, chemotherapy-induced nausea and vomiting; CR, complete response; DEX, dexamethasone; FOS, fosaprepitant; GERSC, granisetron extended-release subcutaneously; GRA, granisetron; HEC, highly emetogenic chemotherapy; IV, intravenously; MTCP, metoclopramide; NA, not achieved; ND, not done; OLN, olanzapine; OND, ondansetron; OPD, olanzapine, palonosetron, dexamethasone; PALO, palonosetron; PO, per os (orally); qd, quaque die (once daily); SC, subcutaneously; tid, ter in die (three times daily).

Table 4 Results of Phase III clinical trials evaluating antiemetic efficacy in CINV prevention following MEC

| Study | Antiemetic treatment and DEX dose | Patient demographics | Primary end-point results | Select secondary end-point results |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Gebbia et al 1994 ⁴⁰ | OND vs GRA day 1: OND 16 mg IV or GRA 3 mg IV | N=164 Mean age 54–57 years, female 78%–80% | OND vs GRA CR acute phase: 69% vs 67%, P=NS | PALO vs OND CR delayed phase: 45% vs 52% |
| Eisenberg et al 2003 ⁴³ | PALO (2 doses) vs DOLA, each + DEX or methylprednisolone PALO (IV) 0.25 mg or 0.75 mg or DOLA 100 mg single DEX 20 mg IV or 20 mg PO or methylprednisolone 125 mg IV allowed | N=592 Age 53–55 years, female 82%–83%, white 30%–33% | PALO vs DOLA CR acute phase: PALO 0.25 mg vs DOLA, 63% vs 52.9%, P=0.049 PALO 0.75 mg vs DOLA, 57.1% vs 52.9%, P=0.412 | PALO vs DOLA PALO 0.25 mg vs DOLA CR delayed phase: 54% vs 38.7%, P=0.004 CR overall phase: 46% vs 34%, P=0.021 PALO 0.75 mg vs DOLA CR delayed phase: 56.6% vs 38.7%, P<0.001 CR overall phase: 47.1% vs 34%, P=0.012 |
| Gralla et al 2003 ⁴⁴ | PALO (2 doses) vs OND PALO 0.25 or 0.75 mg IV or OND 32 mg IV No DEX | N=570 Age ~55–56 years, female 71%–73%, white 98%–100%, nonsmoker 69%–70%, no alcohol use 42%–47%, chemotherapy- naïve 40%–42% | PALO vs OND CR acute phase: PALO 0.25 mg vs OND, 81% vs 68.6%, P=0.0085 PALO 0.75 mg vs OND, 73.5% vs 68.6%, P=0.3067 | PALO vs OND PALO 0.25 mg vs OND CR delayed phase: 74.1% vs 55.1%, P<0.001 Overall phase: 69.3% vs 50.3%, P<0.001 PALO 0.75 mg vs OND CR delayed phase: 64.6% vs 55.1%, P=0.0730 Overall phase: 58.7% vs 50.3%, P=0.1192 |
| Warr et al 2005 ⁴⁵ | OND + APR + DEX vs OND + DEX Day 1: APR 125 mg PO or placebo, OND 8 mg PO before chemotherapy and 8 mg PO after first dose, DEX 12 mg PO Days 2–3: APR 80 mg, placebo PO bid or Day 1: placebo, OND 8 mg PO before chemotherapy and 8 mg PO 8 hours after first dose, DEX 20 mg PO Days 2–3: OND 8 mg PO bid, placebo PO | N=866 Mean age 52–53 years, female 100%, white 78%–80% | APR vs placebo CR overall phase: APR vs placebo, 50.8% vs 42.5%, P=0.015 | APR vs placebo Proportion of patients with functional living index-emesis score >6 of 7 APR regimen vs control regimen Total score: 63.5% vs 55.6%, P=0.019 Vomiting domain: 85.7% vs 71.8%, P<0.001 Nausea domain: 53.5% vs 50.5% |
| Grunberg et al 2009 ⁴⁶ | PALO + APR + DEX PALO 0.25 mg IV + APR 285 mg PO + DEX 20 mg PO | N=41 Median age 51 years, female 98%, chemotherapy-naïve 100% | CR overall phase: 51% | No vomiting Acute phase: 100% Delayed phase: 95% Overall phase: 95% No significant nausea Acute phase: 79% Delayed phase: 59% Overall phase: 56% No nausea Acute phase: 59% Delayed phase: 41% Overall phase: 32% |

(Continued)

Table 4 (Continued)

| Study | Antiemetic treatment and DEX dose | Patient demographics | Primary end-point results | Select secondary end-point results |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aspro et al 2010 ⁶⁷ | PALO with 1-day DEX vs PALO with 3-day DEX Day 1: PALO 0.25 mg IV and DEX 8 mg IV Days 2–3: placebo or DEX 8 mg PO | N=300 Mean age 52 years, female 100% | PALO + 1-day DEX vs PALO + 3-day DEX Noninferiority in CR over days 1–5: 53.6% vs 53.7%, $P=0.487$ | PALO + 1-day DEX vs PALO + 3-day DEX CR acute phase: 69.5% vs 68.5%, $P=0.573$ CR delayed phase: 62.3% vs 65.8%, $P=0.039$ CC overall phase: 71.5% vs 72.5%, $P=0.429$ CC acute phase: 80.1% vs 79.2%, $P=0.583$ CC delayed phase: 78.8% vs 85.2%, $P=0.077$ |
| Rapoport et al 2010 ⁶⁸ | APR + OND + DEX vs placebo + OND + DEX APR regimen Day 1: APR 125 mg PO, OND 8 mg PO prior to chemotherapy and 8 hours after first dose, DEX 12 mg PO Days 2–3: APR 80 mg PO, placebo PO bid Control regimen Day 1: placebo, OND 8 mg PO prior to chemotherapy and 8 hours after first dose, DEX 20 mg PO Days 2–3: OND 8 mg PO bid | N=848 Mean age 56–57 years, female 76%–78% | APR vs placebo No emesis overall phase: APR vs placebo, 76.2% vs 62.1%, $P<0.001$ | APR vs placebo CR overall phase: 68.7% vs 56.3%, $P<0.001$ |
| Celio et al 2011 ⁶⁹ | PALO with 1-day DEX vs PALO with 3-day DEX Day 1: PALO 0.25 mg IV and DEX 8 mg IV Days 2–3: No DEX or DEX 8 mg PO | N=334 Mean age 57 years, female 62%–68%, no alcohol consumption 60%–61% | PALO + 1 day DEX vs PALO + 3-day DEX CR overall phase: 67.5% vs 71.1% Treatment difference –3.6% (95% CI –13.5% to 6.3%), $P=ND$ | PALO + 1 day DEX vs PALO + 3-day DEX CR acute phase: 88.6% vs 84.3%, $P=0.262$ CR delayed phase: 68.7% vs 77.7%, $P=0.116$ No nausea Acute phase: 78.5% vs 72.7%, 95% CI –3.5 to 15.2 Delayed phase: 57.1% vs 62.1%, 95% CI –15.7 to 5.6 Overall phase: 52.1% vs 56.5%, 95% CI –15.2 to 6.5 |
| Boccia et al 2013 ⁷⁰ | PALO PO vs PALO IV PALO (0.25, 0.50, 0.75 mg) PO or PALO 0.25 mg IV, DEX 8 mg IV or placebo | N=651 Mean age 56–58 years, female 72%–74%, chemotherapy-naïve 57%–61%, no alcohol consumption 54%–65% | PALO PO vs IV CR acute phase 0.25 mg PO: 73.5% 0.50 mg PO: 76.3% 0.75 mg PO: 74.1% 0.25 mg IV: 70.4% | PALO PO vs IV CR delayed phase 0.25 mg PO: 59.4% 0.50 mg PO: 62.5% 0.75 mg PO: 60.1% 0.25 mg IV: 65.4% CR overall phase 0.25 mg PO: 53.5% 0.50 mg PO: 58.8% 0.75 mg PO: 53.2% 0.25 mg IV: 59.3% |

| | | | | |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aspro et al 2014 ⁴⁵ | NEPA + DEX vs PALO + DEX NEPA (neupitant 300 mg + PALO 0.50 mg) PO, or PALO 0.50 mg PO Day 1: DEX 12 mg PO with NEPA, or DEX 20 mg PO with PALO | N=1,455 Median age 54 years, female 98%, white 79%–80%, chemotherapy- naïve 100% | NEPA vs PALO CR delayed phase: 76.9% vs 69.5%, P=0.001 | NEPA vs PALO No emesis Acute phase: 90.9% vs 87.3%, P=0.025 Delayed phase: 81.8% vs 75.6%, P=0.004 Overall phase: 79.8% vs 72.1%, P<0.001 No significant nausea Acute phase: 87.3% vs 87.9%, P=0.747 Delayed phase: 76.9% vs 71.3%, P=0.014 Overall phase: 74.6% vs 69.1%, P=0.020 Complete protection Acute phase: 82.3% vs 81.1%, P=0.528 Delayed phase: 67.3% vs 60.3%, P=0.005 Overall phase: 63.8% vs 57.9%, P=0.020 |
| Schmitt et al 2014 ⁷¹ | GRA + APR + DEX vs GRA + DEX APR 125 mg PO day 1, 80 mg PO days 2–4 + GRA 2 mg PO days 1–4 + DEX 4 mg day 1, 2 mg days 2–3 or Placebo + GRA 2 mg PO days 1–4 + DEX 8 mg day 1, 4 mg days 2–3 | N=363 Median age 58 years, female 34%–39% | APR vs placebo CR overall phase: 58% vs 41%, P=0.0042 | APR vs placebo CR acute phase: 97% vs 90%, P=0.022 CR delayed phase: 60% vs 46%, P=0.011 • No emesis within 120 hours: 78% vs 65%, P=0.0036 • No nausea within 120 hours: 85% vs 78%, P=0.106 • Rate of nausea and significant nausea • No impact on daily life: 74% vs 59%, P=0.004 |
| Komatsu et al 2015 ⁷² | PALO with 1-day DEX vs PALO with 3-day DEX PALO 0.75 mg IV + DEX 9.9 mg IV on day 1 Days 2–3: no DEX or DEX 8 mg IV or PO | N=308 Mean age, 64 years, female 43%–43.5%, no alcohol use within 180 days of enrollment 51%–52% | PALO with 1-day DEX vs PALO with 3-day DEX CR overall phase: 63.6% vs 66.2%, P=0.0004 for noninferiority test | PALO with 1-day DEX vs PALO with 3-day DEX CR acute phase: 92.2% vs 93.4% CR delayed phase: 64.9% vs 66.9% CC overall phase: 61.7% vs 64.9% CC acute phase: 92.2% vs 93.4% CC delayed phase: 63.0% vs 65.6% |
| Nishimura et al 2015 ⁷³ | 5HT ₃ RA + DEX vs 5HT ₃ RA + APR or FOS, + DEX Control Day 1: 5HT ₃ RA IV + DEX 9.9 mg Days 2–3: DEX 4 mg bid APR Day 1: APR 125 mg PO, 5HT ₃ RA IV + DEX 6.6 mg Days 2–3: APR 80 mg PO, DEX 2 mg bid For patients receiving FOS Day 1: FOS 150 mg IV, 5HT ₃ RA IV, DEX 6.6 mg Day 2: DEX 2 mg bid PO Day 3: DEX 4 mg bid PO Second cycle: all patients received APR or FOS as above | N=413 Mean age, 64 years, female 80%–81%, chemotherapy-naïve 93% | Control vs APR No emesis, overall phase 83.6% vs 95.7%, P<0.0001 | Control vs APR No nausea Acute phase: 90.2% vs 93.6%, P=0.23 Delayed phase: 61.8% vs 66.3%, P=0.36 Overall phase: 59.6% vs 65.2%, P=0.26 |

(Continued)

Table 4 (Continued)

| Study | Antiemetic treatment and DEX dose | Patient demographics | Primary end-point results | Select secondary end-point results |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Raftopoulos et al 2015 ⁵⁹ | GERSC + DEX vs PALO + DEX GERSC 5 mg or 10 mg SC or PALO (0.25 mg) IV Day 1: DEX 8 mg IV for MEC Days 2–4: DEX PO 8 mg twice daily | N=1,428 Mean age 55–58 years, female 63%–88%, white 56%–67%, chemotherapy–nonnaïve 47%–59% | GERSC vs PALO In cycle 1, MEC GERSC 5 mg SC vs PALO 0.25 mg IV CR acute phase: 74.8% vs 75.0%, P=1.0 CR delayed phase: 51.4% vs 57.2%, P=0.24 GERSC 10 mg SC vs PALO 0.25 mg IV CR acute phase: 76.9% vs 75.0%, P=0.73 CR delayed phase: 58.5% vs 57.2%, P=0.84 | GERSC vs PALO CR overall phase, MEC GERSC 5 mg SC vs PALO 0.25 mg IV: 48.6% vs 51.9%, 95% CI –2.9 to 6.2 GERSC 10 mg SC vs PALO 0.25 mg IV: 53.8% vs 51.9%, 95% CI –7.8 to 11.4 |

Note: NEPA, APR, and PALO administered 60 minutes prior to chemotherapy administration on day 1.
Abbreviations: 5HT₃, 5-hydroxytryptamine type 3; APR, aprepitant; bid, bis in die (twice daily); CC, complete control; CINV, chemotherapy-induced nausea and vomiting; CR, complete response; DEX, dexamethasone; DOLA, dolasetron; FOS, fosaprepitant; GRA, granisetron; GERSC, granisetron extended-release subcutaneously; IV, intravenously; MEC, moderately emetogenic chemotherapy; ND, not done; NEPA, fixed-dose netupitant + palonosetron; NS, not significant; OND, ondansetron; PALO, palonosetron; PO, per os (orally); RA, receptor antagonist; SC, subcutaneously.




Figure 1 Extended-release formulations of granisetron: plasma granisetron concentrations following administration.
Notes: Data from these studies.^{29–31,79} Dashed line indicates minimum therapeutic concentration of granisetron 2 ng/mL (data from patent application 20120258164 for granisetron transdermal delivery system).

bioerodible tri(ethylene glycol) poly(orthoester) (TEG-POE) polymer.⁸⁴ The POE polymer contains an orthoester linkage that is hydrolyzed to excreted fragments on exposure to an aqueous environment. The acid-labile nature of the TEG-POE polymer allows granisetron release by diffusion from the depot followed by controlled polymer hydrolysis, resulting in further release of granisetron.⁸⁵ In healthy subjects, granisetron is released from the polymer over an extended period (C_{max} occurring approximately 10 hours after administration) (Figure 1). The biphasic drug release from the polymer provides granisetron exposure into the delayed phase of CINV, with mean plasma concentration of 3.5 ng/mL (range 0–14 ng/mL) 5 days after a single 10 mg dose (Figure 2).²⁹ Following a single SC injection of GERSC to patients with cancer, time to C_{max} was reported as occurring approximately 24 hours postdose, and the $t_{1/2}$ of granisetron was 26–34 hours.³⁰ The difference in reported time to C_{max} in healthy subjects and patients with cancer may be an artifact of the small number of participants in these analyses and the timing of blood samples used to estimate these pharmacokinetic parameters. Overall, GERSC provides slow, controlled release of therapeutic granisetron concentrations for ≥ 5 days following a single SC injection.^{30,84} The efficacy of GERSC in CINV prevention during acute and delayed phases following MEC or HEC has been shown in two large Phase III trials.^{54,59,86} In contrast to GTDS, which is applied 24–48 hours prior to chemotherapy,³¹ GERSC may be given shortly (≥ 30 minutes) before chemotherapy (Table 2). However, the GERSC single-dose syringe must be prepared at least 60 minutes prior to SC administration by warming the viscous liquid to room temperature, and the contents must be injected slowly by a health-care professional. A topical




Figure 2 Biochronomer technology mechanism of action.

anesthetic may be applied to the injection site (IS) prior to administration.²⁹

Clinical trial experience has established that 5HT₃ RAs effectively control emesis in the acute phase,^{87–90} but their efficacy in the delayed phase is limited.^{91,92} In Phase III trials, the addition of the NK₁ RA aprepitant to a regimen of a 5HT₃ RA plus dexamethasone improved CINV control over both acute and delayed phases following MEC or HEC (Tables 3 and 4).^{55,56,68,93} In the Phase III MAGIC trial of GERSC versus ondansetron, each combined with an NK₁ RA and dexamethasone, the GERSC regimen provided superior delayed-phase CR in patients receiving HEC compared with the ondansetron regimen,⁵⁴ suggesting the involvement of 5HT₃ RAs in mitigating delayed as well as acute CINV.

Efficacy of combination therapies for CINV

The three-drug antiemetic regimen (5HT₃ RA + NK₁ RA + dexamethasone)

Currently, guidelines for CINV prevention following HEC recommend a three-drug regimen of a 5HT₃ RA, an NK₁ RA, and dexamethasone as an option, with NCCN and ASCO guidelines also proposing a four-drug regimen with the addition of olanzapine (Table 1). No 5HT₃ RA as a part of a three-drug regimen is preferred by any guideline for HEC.^{7,17,19} Efficacy results from key Phase III trials in patients receiving HEC are summarized in Table 3. The MAGIC trial was the first Phase III registrational efficacy study to compare single doses of two 5HT₃ RAs – GERSC and

ondansetron – in a guideline-recommended three-drug versus three-drug regimen in 942 randomized patients receiving HEC⁵⁴ (Table 3). As expected from the ER design, compared with the ondansetron arm, the GERSC arm demonstrated a superior delayed-phase CR rate (64.7% vs 56.6%, $P=0.014$, absolute treatment difference 8.0%), challenging the view that 5HT₃ RAs have equal efficacy in delayed-phase CINV prevention following HEC.^{11,94} Consistent with the primary end point of CR, the GERSC arm versus the ondansetron arm also showed benefit in reducing rescue medication use and nausea frequency in the delayed and overall CINV phases.⁵⁴ Additionally, patient-reported satisfaction with antiemetic therapy was significantly higher in the GERSC arm versus the ondansetron arm in the delayed phase.⁵⁴

Because all patients in the MAGIC trial were from US community practices, these results are likely to be representative of outcomes in that practice setting. Importantly, the GERSC regimen demonstrated superiority to the ondansetron regimen in a population where the majority of patients were women (GERSC arm 79.6%, ondansetron arm 82.5%), a high-risk group for CINV.⁵⁴ Moreover, patients were stratified by planned use of cisplatin (≥ 50 mg/m², yes/no), and the delayed-phase CR rate was higher in the GERSC arm (65.3%) versus the ondansetron arm (54.7%) in the 252 patients in the cisplatin stratum.⁵⁴ In a post hoc subgroup analysis of the 589 patients (65%) receiving AC-based HEC, at least 98% of whom were women, delayed-phase CR rates showed a trend favoring the GERSC arm (64%) over the ondansetron arm (56%).⁹⁵ A similar trend was found in the subgroup of 252 patients scheduled to receive cisplatin, where delayed-phase CR rates were numerically higher in the GERSC arm (65%) than in the ondansetron arm (55%).⁹⁶ These subgroup findings were consistent with the overall population, although the analyses were not powered to show a significant difference between groups.

The two-drug antiemetic regimen (5HT₃ RA + dexamethasone)

Guidelines for CINV prevention following MEC generally recommend a two-drug regimen of a 5HT₃ RA plus dexamethasone on day 1 (with or without an NK₁ RA) and dexamethasone on days 2 and 3, with NCCN guidelines proposing the addition of an NK₁ RA for patients with additional CINV risk factors or prior treatment failure.^{7,18,19} Efficacy results from key Phase III trials in patients receiving MEC are summarized in Table 4. In the Phase III trial of GERSC compared with palonosetron, both in combination with dexamethasone, in patients receiving MEC (reanalyzed according to 2011

ASCO criteria⁹⁷), both doses of GERSC (5 mg and 10 mg SC) were noninferior to palonosetron (0.25 mg IV) in preventing acute-phase CINV as determined by CR in cycle 1 of chemotherapy, and the 10 mg dose of GERSC was noninferior to palonosetron in preventing CINV in the delayed phase.⁸⁶

Of interest, because of AEs associated with dexamethasone, such as insomnia, gastrointestinal symptoms, agitation, increased appetite, and weight gain,⁹⁸ several studies have investigated the efficacy of a dexamethasone-sparing palonosetron regimen involving 1-day versus 3-day dexamethasone in the MEC setting and reported the noninferiority of these regimens (Table 4).^{67,69,72}

Nausea control

Significant advances have been made in emesis control following MEC or HEC with the use of newer agents, but nausea control following HEC remains suboptimal, especially in the delayed phase of CINV, with delayed nausea being reported by 68% of patients in one study.¹⁰ A multinational survey of 2,388 health-care providers found delayed nausea to be most challenging to prevent,⁵ and several patient-related factors, including younger age, type of cancer, and patient's perceived susceptibility to nausea, can contribute to increased incidence of chemotherapy-induced nausea.⁹⁹ Subjectivity in the measurement of nausea and its severity and a lack of understanding of underlying mechanisms pose barriers to optimal nausea control. In clinical trials, such end points as CC (CR with no more than mild nausea) and total response (CR with no nausea) provide some measure of nausea control, but rely on the patient's self-reporting of nausea frequency and severity.

In the MAGIC trial of GERSC, patients with CC in the delayed phase comprised 60.7% in the GERSC regimen and 53.1% in the ondansetron regimen, a treatment difference of 7.6% (95% CI 1.1%–14.0%, unadjusted $P=0.022$). Percentages of CC were also higher in the GERSC regimen than the ondansetron regimen in the overall phase, but the difference was not significant (54.7% vs 49.6%, respectively; unadjusted $P=0.123$). The proportions of patients with no nausea in the GERSC and ondansetron regimens were similar in the delayed (49.7% vs 44.2%, respectively; $P=0.099$) and overall phases (45.3% vs 40.5%, respectively; $P=0.138$).⁵⁴

A recent Phase III trial of olanzapine versus placebo, each with a three-drug regimen of a 5HT₃ RA, an NK₁ RA, and dexamethasone, focused specifically on nausea control as the primary end point, and showed effective nausea control with the olanzapine regimen compared with the placebo regimen in patients receiving cisplatin or AC-based HEC. For patients in the olanzapine group compared with the placebo group,

the proportions of patients with no nausea (acute phase 74% vs 45%, respectively, $P=0.002$; delayed phase 42% vs 25%, $P=0.002$; overall phase 37% vs 22%, $P=0.002$) and with CR (acute phase 86% vs 65%, $P<0.001$; delayed phase 67% vs 52%, $P=0.007$; overall phase 64% vs 41%, $P<0.001$) were significantly higher across all CINV phases.¹⁵

Efficacy of 5HT₃ RAs in multicycle chemotherapy

In trials evaluating antiemetics in multicycle-chemotherapy settings, the efficacy of 5HT₃ RAs in CINV prevention was generally maintained over multiple cycles (Table 5^{37,80,100–102}). Palonosetron at a dose of 0.75 mg, which is three times the approved dosage in the USA, was generally well tolerated in a Phase III trial in patients receiving cisplatin or AC-based HEC in Japan (Table 5).¹⁰⁰ CR rates were maintained across four cycles in the acute (range 72%–77%), delayed (range 56%–63%), and overall (range 52%–56%) phases.¹⁰⁰ A single-arm study in 156 patients receiving four to six cycles of cisplatin-based HEC evaluated CINV-prevention efficacy of palonosetron 0.25 mg IV in a three-drug regimen with oral aprepitant 125 mg and dexamethasone 20 mg IV on day 1. Overall-phase CR rates were maintained over six cycles, ranging from 74.4% to 82.0%. At least 90% of patients had no emesis, and at least 60% had no nausea across cycles.¹⁰³ The proportion of high-risk female patients in this study was 36%.

In a Phase III study of NEPA over multiple cycles, oral NEPA plus oral dexamethasone was compared with a control regimen of oral aprepitant plus oral palonosetron plus oral dexamethasone³⁷ (Table 5). Overall-phase CR rates were maintained over multiple cycles in patients receiving the NEPA regimen (HEC 79%–91%, MEC 80%–93%) or the control regimen (HEC 58–86%, MEC 82%–89%), and were slightly lower with the latter regimen. In the delayed phase, there was a small but consistent numerical advantage in CR of 2%–6% with the NEPA regimen compared with the control regimen. The proportion of patients with no significant nausea in the overall phase remained high in both groups. Around 50% of study patients were women, and overall-phase CR rates with the NEPA regimen were generally similar in men and women across cycles (data not shown).³⁷

In a Phase III trial in patients receiving multiple cycles of MEC or HEC, sustainability of GERSC efficacy in CINV prevention was examined. Patients received GERSC 5 or 10 mg SC or palonosetron 0.25 mg IV in cycle 1. After cycle 1, no palonosetron was administered, and upon consent patients previously receiving palonosetron were rerandomized to receive GERSC 5 or 10 mg SC. CR rates were sustained

over four cycles in patients receiving GERSC 10 mg once per cycle, with CR rates of 68.4% in patients in the acute phase of CINV, and 57.9% in the delayed phase following HEC; corresponding CR rates in patients receiving MEC were 56.5% and 41.3%, respectively. Emesis control was comparable to nausea control in patients receiving GERSC. Among patients in the MEC and HEC groups, respectively, 84%–88% and 63%–67% were women.¹⁰¹ The higher proportion of women in the MEC group versus the HEC group and inclusion of AC-based regimens as MEC (as per guidelines at the time of the study design⁸) instead of HEC (as per current guidelines^{7,17,19}) may have contributed to the lower CR rates in the MEC group compared with those in the HEC group. At the time of this study, the recommended antiemetic regimen for patients receiving multiple cycles of HEC did not include an NK₁ RA. The efficacy of GERSC as a part of a three-drug regimen remains to be investigated in the setting of multicycle MEC or HEC.

Efficacy of 5HT₃ RAs in multiday chemotherapy

There have been fewer trials evaluating the antiemetic efficacy of 5HT₃ RAs in patients receiving multiday chemotherapy than in those receiving single-day chemotherapy, and the NCCN guidelines recognize the lack of evidence to support recommendations in multiday-chemotherapy settings.⁷ The efficacy of transdermal (GTDS) versus oral granisetron in preventing CINV was investigated in a Phase III study of 641 patients receiving their first cycle of a multiday MEC or HEC regimen (Table 5).⁸⁰ GTDS was noninferior to daily oral granisetron, and efficacy was maintained across the multiday-chemotherapy regimen (CC, GTDS 60%, oral granisetron 65%, 95% CI –13 to 3).⁸⁰ A small Phase III CINV-prevention study in 69 patients receiving 5-day cisplatin showed a significantly higher CR rate with a regimen of the NK₁ RA aprepitant plus a 5HT₃ RA (excluding palonosetron) plus dexamethasone versus a 5HT₃ RA plus dexamethasone (42% vs 13%, $P<0.001$) (Table 5).¹⁰²

In a retrospective trial of palonosetron in comparison with ondansetron in patients receiving multiday cisplatin or carboplatin, palonosetron therapy was associated with a 63% lower risk of uncontrolled CINV (odds ratio 0.37, 95% CI 0.25–0.54; $P<0.0001$).¹⁰⁴ A pilot study involving administration of palonosetron 0.25 mg IV for 1, 2, or 3 days in patients receiving multiday high-dose melphalan and hematopoietic stem-cell transplantation suggested that multiple doses may be more effective than a single dose.¹⁰⁵ However, these results need confirmation in larger trials in combination with NK₁ RAs.

Table 5 Results of prospective Phase III clinical trials evaluating antiemetic efficacy in CINV prevention following multicycle or multiday chemotherapy

| Study, treatment | Antiemetic treatment and DEX dose | Patient demographics | Primary end-point result | Select secondary end-point result |
|----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Multicycle chemotherapy | | | | |
| Aogi et al 2012 ¹⁰⁰ Multiple cycles of cisplatin or AC | PALO + DEX PALO 0.75 mg IV Day 1: DEX 16 mg IV Days 2–3: DEX 8 mg IV (cisplatin-treated patients) or 4 mg PO for AC-treated patients | N=546 Mean age 58 years, female 57%, no alcohol consumption within 180 days of enrollment 44% | Treatment-related AEs: 44% of patients Serious AEs: 4% Study discontinuation due to treatment-related AEs: 1 No trend toward worsening AEs through successive cycles | PALO + DEX CR across cycles Acute phase: 77.0%–71.7% Delayed phase: 56.0%–62.6% Overall phase: 51.6%–56.1% |
| Gralla et al 2014 ³⁷ Multiple cycles of MEC or HEC | NEPA + DEX vs PALO + APR + DEX NEPA ^a (netupitant 300 mg + PALO 0.5 mg) PO + DEX or APR (125 mg PO day 1 80 mg days 2–3) + PALO 0.5 mg PO day 1 + DEX DEX PO for HEC Day 1: 12 mg Days 2–4: 8 mg DEX PO for MEC Day 1: 12 mg | N=413 Median age 57–59 years, female 49%–50% | Most frequent NEPA-related AEs: constipation (3.6%) and headache (1.0%); AEs did not increase over multiple chemotherapy cycles, most were mild–moderate; no cardiac safety concerns, no deaths related to study drug | NEPA + DEX vs APR + PALO + DEX CR overall phase Cycles 1: 81% vs 76% 2: 86% vs 81% 3: 91% vs 87% 4: 90% vs 88% 5: 92% vs 86% 6: 91% vs 86% CR overall phase for HEC across cycles NEPA: 79%–91% APR + PALO: 58%–86% CR overall phase for MEC across cycles NEPA: 80%–93% APR + PALO: 82%–89% No significant nausea Overall phase NEPA: 84%–92% APR, PALO: 81%–87% |
| Boccia et al 2015 ¹⁰¹ Multiple cycles of MEC or HEC | GERSC + DEX vs PALO + DEX Cycle 1 GERSC 10 mg SC + placebo IV or GERSC 5 mg + placebo IV or PALO 0.25 mg IV + placebo SC No PALO after cycle 1: patients on PALO rerandomized 1:1 to GERSC 10 mg or 5 mg, upon consent DEX Day 1: 8 mg IV for MEC, 20 mg IV for HEC Days 2–4: 8 mg bid PO for HEC | N=1,428 Mean age 55–58 years, female 63%–88%, white 58%–68% | Post hoc analysis Across four cycles, per cycle GERSC 10 mg, HEC CR acute phase: 81.3%–87.8% CR delayed phase: 67.1%–83.1% Sustained CR over four cycles GERSC 10 mg, HEC CR acute phase: 68.4% CR delayed phase: 57.9% GERSC 10 mg, MEC CR acute phase: 56.5% CR delayed phase: 41.3% Cycle 1 PALO CR acute phase for MEC: 75% CR acute phase for HEC: 81% | |

| Multiday chemotherapy | | | |
|----------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Boccia et al 2011 ⁸⁰ Multiday MEC or HEC | GTDS vs GRA PO Granisetron transdermal delivery system (GTDS), one patch, 7 days or GRA PO 2 mg/d, 3–5 days No DEX use information available | N=641 Mean age 54–55 years, female 16%–17%, white 25%–26%, never-smokers 17%–19%, no alcohol use 22%–23%, chemotherapy-naïve 22%–23% | GTDS vs GRA PO CR (per protocol data set) 62% vs 68%, 95% CI –14.4 to 1.3 Patch adhesion ≥90% adhesion: 64% vs 78% ≥75% adhesion: 90% vs 96% Complete detachment: 1% vs 1% |
| Albany et al 2012 ⁸² Two consecutive courses of 5 days cisplatin combination therapy | APR + 5HT ₃ RA + DEX vs 5HT ₃ RA + DEX + placebo (three-drug regimen, excluding PALO) Days 1–2: DEX 20 mg PO qd Days 1–5: 5HT ₃ RA (excluding PALO) APR Day 3: APR 125 mg PO Days 4–7: APR 80 mg Days 6–7: DEX 4 mg bid Day 8: DEX 4 mg bid Placebo Days 3–5: placebo Days 6–7: placebo, DEX 8 mg bid Day 8: DEX 4 mg bid | N=69 Median age 33 years, chemotherapy-naïve 83% | GTDS vs GRA PO First cycle of multiday chemotherapy (MEC or HEC) CC (from first chemotherapy to 24 hours after last chemotherapy administration, per protocol data set): 60% vs 65%, 95% CI –12.9 to 3.1 DEX + placebo CR acute phase (days 1–5): 47% vs 15%, P<0.001 CR delayed phase (days 6–8): 63% vs 35%, P<0.001 CR overall phase (days 1–8): 42% vs 13%, P<0.001 APR + 5HT ₃ RA + DEX vs 5HT ₃ RA + DEX + placebo Emesis APR cycle vs control cycle: 16.2% vs 47.1% Patient-preferred APR cycle vs placebo cycle: 55% vs 16%, P<0.001 |

Note: ^aNEPA, APR, and PALO administered 60 minutes prior to chemotherapy administration on day 1.

Abbreviations: 5HT₃, 5-hydroxytryptamine type 3; AC, anthracycline–cyclophosphamide; AE, adverse event; APR, aprepitant; bid, bis in die (twice daily); CC, complete control; CINV, chemotherapy-induced nausea and vomiting; CR, complete response; DEX, dexamethasone; GRA, granisetron; GERSC, granisetron extended-release subcutaneously; GTDS, granisetron transdermal system; HEC, highly emetogenic chemotherapy; IV, intravenously; MEC, moderately emetogenic chemotherapy; NEPA, fixed-dose netupitant + palonosetron; PALO, palonosetron; PO, per os (orally); qd, quaque die (once daily); RA, receptor antagonist; SC, subcutaneously.

Factors affecting the efficacy of 5HT₃ RAs in prevention of acute and delayed CINV

In addition to chemotherapy emetogenicity, patient-related risk factors influence CINV and may affect outcomes in clinical studies. These factors include female sex,¹⁰⁶ younger age,⁹⁹ history of low alcohol consumption,¹⁰⁷ history of motion sickness,¹⁰⁷ and history of previous chemotherapy-induced emesis.¹¹ As such, young female patients receiving HEC are at particularly high risk of experiencing CINV,¹⁰⁸ and differences in proportions of female patients in clinical studies may affect results. The development of predictive tools with a simple scoring system to identify patients at higher risk for CINV, based on a combination of patient- and chemotherapy-related risk factors, may assist in determining the most suitable antiemetic regimen for patients.¹⁰⁹

Genetic variation in 5HT₃ receptors or molecules involved in their transport and metabolism may also lead to differences in antiemetic efficacy.^{110,111} 5HT₃-RA metabolism is dependent on enzymes in the CYP450 family, with certain enzymes playing a dominant role in certain drugs.^{112–114} For example, palonosetron and dolasetron are metabolized primarily by CYP2D6, whereas granisetron is metabolized primarily by CYP1A1;^{110,115,116} there is no dominant CYP450 enzyme for metabolizing ondansetron.^{110,112} CYP2D6 is also involved in the metabolism of a variety of drug classes, and genetic polymorphisms lead to alleles with different activities (defective, decreased, or increased), resulting in poor, intermediate, extensive, or ultrarapid metabolizers (UMs).^{111,115} The frequency of UMs varies by race, and control of chemotherapy-induced vomiting using ondansetron or tropisetron is weakest in UM patients compared with poor or intermediate metabolizers.¹¹⁷ A pharmacogenetically driven treatment pathway that accounts for CYP2D6 genotype has been proposed, suggesting that patients classed as CYP2D6 UMs receiving MEC or HEC should be given granisetron as the first-line 5HT₃ RA to circumvent the CYP2D6 pathway and reduce pharmacokinetic and pharmacodynamic variability.¹¹⁵ It has been suggested that genetic polymorphisms of CYP3A4 among patients from different races influence granisetron exposure and thereby its efficacy.¹¹⁴ Because the ER formulation of GERSC allows continuous exposure to granisetron, it may reduce interpatient variability in antiemetic efficacy resulting from differences in granisetron metabolism. Genetic variations in *5HT3R* may also exist, which may explain in part the decreased efficacy of 5HT₃ RAs in some patients.¹¹⁵ Additional prospective studies investigating 5HT₃-receptor polymorphisms and

drug transporters may further elucidate the role of genetics in antiemetic response.

Safety of 5HT₃ RAs Most common AEs

The safety profile of 5HT₃ RAs is well documented, and these agents are typically well tolerated. The most commonly reported AEs associated with IV or PO 5HT₃ RAs are headache (0–24%, depending on the agent and formulation) and constipation (0–14%) (Table 6^{25,27–29,31–33,36}).^{25,28,29,31–34,36} Diarrhea, asthenia, and dyspepsia are other known AEs. The incidence of these AEs is generally similar across the 5HT₃ RAs^{59,118,119} (Table 6), and they are generally mild and manageable. In IV and oral formulations of 5HT₃ RAs, headache is reported more frequently than constipation, but in the MAGIC trial of GERSC, this finding was reversed. In the Phase III MAGIC trial, constipation occurred in 22% of patients in the GERSC arm and 15% of patients in the ondansetron IV arm, while headache was less common (12% vs 18%, respectively).⁵⁴ Similar trends were observed with GTDS, which also provides ER granisetron: a higher proportion of GTDS-treated versus oral granisetron-treated patients (7% vs 3%) had constipation, whereas a lower proportion had headache (0.3% vs 2.5%).⁸⁰

Hypersensitivity and injection-site reactions

Hypersensitivity reactions and IS reactions (ISRs) have been reported with all 5HT₃ RAs. Extremely rare instances (<1/10,000) of hypersensitivity, including anaphylaxis and ISRs, have been reported from postmarketing experience with palonosetron IV.³⁴ Rare and sometimes severe cases of hypersensitivity have been reported with IV granisetron (eg, anaphylaxis, hypotension, shortness of breath, and urticaria)²⁵ and ondansetron IV (eg, anaphylactic reactions, angioedema, bronchospasm, cardiopulmonary arrest, hypotension, laryngospasm, shock, shortness of breath, and stridor).³² ISRs, including pain, redness, and burning, have also been reported with ondansetron IV.³²

The Phase III trial of GERSC versus palonosetron IV in preventing CINV in patients receiving MEC or HEC showed that the safety profiles of these two agents were similar.⁵⁹ The most common treatment-related AEs were ISRs (GERSC 10 mg SC 38.9%, palonosetron 11.2%), constipation (GERSC 10 mg SC 4.5%, palonosetron 3.0%), and headache (GERSC 10 mg SC 2.8%, palonosetron 1.9%).⁵⁹

In the Phase III MAGIC trial, GERSC was also generally well tolerated compared with ondansetron IV, and no

Table 6 Percentage of patients (≥2%) with AEs using 5HT₃ RA, based on drug-prescribing information

| Drug, n | Headache, % | Constipation, % | Diarrhea, % | Asthenia, % | Fatigue, % | Dyspepsia, % | Dizziness, % | Pain, % | Other AEs, % |
|-----------------------------------------------------------------------------------------------|-------------------------|------------------------------|------------------------|------------------------|--------------------------|------------------------|------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Dolasetron 100 mg PO n=227 ²⁷ | 22.9 | — | 5.3 | — | 5.7 | 2.2 | 3.1 | 3.1 | Bradycardia, 4.0 Tachycardia, 2.6 Chills, 2.2 Somnolence, 4 |
| Granisetron 40 µg/kg IV ^a n=1,268 ²⁵ | 14 | 3 | 4 | 5 | — | — | — | — | Dyspepsia, 6 Elevated (>2× normal values) levels AST (5) and ALT (6) Insomnia, 5 Fever, 5 |
| Granisetron 2 mg once daily PO ^b n=1,450 ²⁸ | 20 | 14 | 9 | 18 | — | 6 | 5 | 4 (abdominal) | Injection-site reactions, (including bruising, pain, erythema, mass or nodule, capillary bleeding), 37–62 |
| GERSC SC, 10 mg granisetron ^c n=468, n=456 ²⁹ | 9 (N=486) 13 (N=456) | 14 (N=468) 22 (N=456) | 8 (N=468) 9 (N=456) | 4 (N=468) 2 (N=456) | 11 (N=468) 21 (N=456) | 3 (N=468) 6 (N=456) | 3 (N=468) 5 (N=456) | 7 (N=468) 7 (N=456), abdominal | Fever, 8 Elevated (>2× normal values) levels AST and ALT, ~5 |
| GTDS transdermally ^c n=404 ³¹ | — | 5.4 | — | — | — | — | — | — | — |
| Ondansetron IV (three 0.15 mg/ kg doses) ^b n=419 ³² | 16 | 11 (multiday ondansetron) | 16 | — | — | — | — | — | — |
| Ondansetron 24 mg once daily PO (HEC) ^d n=300 ³³ | 11 | — | 4 | — | — | — | — | — | — |
| Ondansetron 8 mg twice daily for 3 days, PO (MEC) ^e n=242 ³³ | 24 | 9 | 6 | — | 13 | — | 5 | — | — |
| Palonosetron 0.25 mg IV n=633 ³² | 9 | 5 | — | — | — | — | — | — | — |
| Palonosetron + netupitant (NEPA), PO n=136 (HEC), ^c n=725 (AC) ³⁶ | — (N=136) 9 (N=725) | 3 (N=136) — (N=725) | — | — (N=136) 8 (N=725) | 4 (N=136) 7 (N=725) | 4 (N=136) — (N=725) | — | — | Erythema, 3 (N=136) |

Notes: ^aAEs in >3% of patients; ^bAEs in >5% of patients; ^cAEs in ≥3% of patients; ^dAEs in ≥4% of patients; ^eAEs in ≥5% of patients.

Abbreviations: 5HT₃, 5-hydroxytryptamine type 3; AC, anthracycline–cyclophosphamide; AEs, adverse events; ALT, alanine transaminase; AST, aspartate transaminase; GERSC, granisetron extended-release subcutaneously; GTDS, granisetron transdermal system; HEC, highly emetogenic chemotherapy; IV, intravenously; MEC, moderately emetogenic chemotherapy; NEPA, fixed-dose netupitant 300 mg + palonosetron 0.5 mg; PO, per os (orally); RA, receptor antagonist; SC, subcutaneously.

unexpected safety findings were observed.⁵⁴ All ISRs were conservatively considered treatment-related, regardless of their time of occurrence following study-drug administration, and were graded by investigators on days 1 and 6 and at the final safety follow-up visit according to prespecified criteria representing only size differences, not functional impairment.⁵⁴ Additionally, patients were instructed to evaluate the IS on days 2 to 5 and record the ISR status in a provided diary. ISRs occurred in patients in both arms at a similar frequency (61.8% in the GERSC arm, 59.5% in the ondansetron arm), presumably because of the double-dummy design of the study, where both arms received SC and IV drug or vehicle placebo; most ISRs were mild–moderate and resolved over time.⁵⁴ No ISRs led to study discontinuation or death.⁵⁴

Compared with the earlier Phase III trial, a greater proportion of patients receiving GERSC in the MAGIC trial reported ISRs.^{54,59} Several factors may have contributed to this finding, including the assumption that all ISRs were treatment-related, grading only according to size and not functional impairment (which may have led investigators to pay greater attention to ISRs), and the instruction for patients to evaluate the site and record any signs of ISRs in patient diaries. Further, the MAGIC trial was conducted only in the USA, whereas the previous trial also included patients from Poland and India;^{54,59} potential differences in ISR reporting across countries may have led to the observed ISR-reporting differences in the studies. The most common ISR in both trials was bruising, which was higher in the MAGIC trial (GERSC arm 41.9%, ondansetron arm 33.6%) than in the previous Phase III trial (GERSC 10 mg, related 15.6%, unrelated 4.3%; palonosetron 0.25 mg IV, related 6.5%, unrelated 2.6%).^{54,59} However, if ISRs in the MAGIC trial were graded by National Cancer Institute Common Terminology Criteria for AEs instead of size, all instances of IS bruising of grades 2 and 3 would have been classified as grade 1. A Phase I crossover study demonstrated that GERSC may be administered to the abdomen or nondominant upper arm, but ISR incidence was higher in patients receiving abdominal (84.5%) versus upper-arm injections (69.2%).¹²⁰ Therefore, upper-arm administration may be preferable.

Serotonin syndrome

5HT₃ RAs have been associated with serious AEs, such as serotonin syndrome (involving symptoms of mental status changes), autonomic instability, neuromuscular symptoms, and seizures with or without gastrointestinal symptoms.^{25,32–34,36} Serotonin syndrome results from increased serotonin signaling in the central nervous system.¹²¹

Occurrences of serotonin syndrome have generally been associated with concomitant use of serotonergic drugs and 5HT₃ RAs or with an overdose of 5HT₃ RAs.³³ Some fatalities resulting from serotonin syndrome have been reported with 5HT₃ RAs.¹²¹ Patient monitoring for symptoms of serotonin syndrome and discontinuation of 5HT₃ RAs on their occurrence is recommended.

Cardiac effects

As a class, 5HT₃ RAs block cardiac hERG potassium channels with varying effectiveness,⁸³ so may be associated with abnormal cardiac electrical activity, such as a prolonged QT interval on electrocardiography (ECG). Dolasetron and ondansetron have lower clinical cardiac safety margins compared with granisetron and palonosetron.⁸³ In 2010, the FDA requested the withdrawal of the CINV indication for dolasetron IV, because of the possibility of life-threatening cardiac arrhythmias, such as QT-interval prolongation.⁷⁴ In 2012, the FDA restricted IV doses of ondansetron to three doses of 0.15 mg/kg administered every 4 hours to a maximum of 16 mg, given the risk of QT-interval prolongation.¹²² Postmarketing reports of torsades de pointes have also been documented in patients using ondansetron.³²

Other 5HT₃ RAs have demonstrated no clinically significant changes in QT interval. Palonosetron 0.25, 0.75, or 2.25 mg IV showed no significant effect on cardiac QT intervals in healthy volunteers.¹²³ Supratherapeutic doses of NEPA (netupitant 600 mg and palonosetron 1.5 mg) produced no significant change in QTc, PR, or QRS intervals in healthy volunteers.¹²⁴ In a thorough QT/QTc study in healthy volunteers, granisetron administered via GTDS achieved prolonged therapeutic plasma concentrations compared with granisetron IV, but this did not lead to significant or progressive QT prolongation.¹²⁵ In a similar study, GERSC 20 mg (twice the approved dose) elicited no clinically significant effect on QT interval compared with placebo.¹²⁶ Although ECG changes induced by 5HT₃ RAs can be asymptomatic and reversible, fatal cardiac arrhythmias can occur in certain cases.¹²⁷ NCCN guidelines recommend that patients at high risk of developing life-threatening cardiac arrhythmias, such as those with torsades de pointes, receive routine ECG monitoring during treatment with 5HT₃ RAs.⁷

Special populations

For ondansetron IV and PO and palonosetron IV, no dosage adjustment is recommended for patients with renal impairment or mild–moderate hepatic impairment.^{32–34} In patients with severe hepatic impairment (Child–Pugh score ≥10), the

maximum total daily dose of ondansetron should not exceed 8 mg.^{32,33} For NEPA, no dosage adjustment is necessary in patients with mild–moderate renal or hepatic impairment, but NEPA should be avoided in patients with severe hepatic or renal impairment or end-stage renal disease.³⁶ Total granisetron clearance is not affected in patients with severe renal failure receiving a single IV dose of granisetron, and no dosage adjustment is necessary in patients with hepatic impairment.²⁵ For granisetron PO, no dosage adjustment is recommended for patients with either renal or hepatic impairment.²⁸ No studies have investigated the pharmacokinetics of GTDS in patients with renal or hepatic impairment.³¹ For GERSC, there are no pharmacokinetic data on the elimination of the TEG-POE polymer vehicle in patients with renal impairment, and the clinical significance of prolonged granisetron elimination in patients with cancer is unknown. Consequently, current recommendations are that GERSC should not be administered more than once every 14 days in patients with moderate renal impairment and should be avoided in patients with severe renal impairment.²⁹

Clearance of ondansetron IV in pediatric patients aged 1–4 months is slower, and the $t_{1/2}$ is ~2.5-fold longer than in patients aged >4–24 months, so patients <4 months old receiving ondansetron IV should be closely monitored.³² The safety and effectiveness of ondansetron PO have been established in pediatric patients ≥4 years of age receiving MEC, but not HEC.³³ The safety and effectiveness of palonosetron IV have been established in pediatric patients aged 1 month to <17 years. Pediatric patients require a higher IV dose of palonosetron than adults to prevent CINV, but the safety profile is consistent with that in adults.³⁴ For NEPA, safety and effectiveness in patients <18 years of age have not been established. For granisetron, the recommended IV dose in pediatric patients 2–16 years of age is 10 µg/kg. Benzyl alcohol, a component of granisetron 1 mg/mL IV, has been associated with serious adverse reactions and death, particularly in neonates.²⁵ The safety and effectiveness of granisetron PO, GTDS, and GERSC in pediatric patients have not been established.^{28,29,31}

For ondansetron IV and PO, no overall differences in safety or effectiveness have been observed between elderly and younger patients, and no dosage adjustment is needed in patients >65 years of age. However, greater sensitivity of some older patients to ondansetron cannot be ruled out.^{32,33} Population pharmacokinetic analyses of palonosetron IV have not revealed any differences between patients ≥65 years of age and younger adult patients.³⁴ For NEPA PO, the safety profiles in elderly and younger patients are similar.³⁶ For different formulations of granisetron, the safety and effec-

tiveness of granisetron IV and PO are similar in patients of various ages.^{25,28} For GTDS and GERSC, clinical experience has not identified any differences in safety or effectiveness between elderly and younger patients.^{29,31} In general, caution should be used when administering any of these agents to elderly patients, because of their increased likelihood of having decreased hepatic, renal, or cardiac function, concomitant diseases, and receiving other drug therapies.

Safety of 5HT₃ RAs in multicycle chemotherapy

5HT₃ RAs have generally been well tolerated in multicycle CINV-prevention trials. NEPA was generally safe when administered over multiple cycles to patients receiving MEC: the incidence of AEs did not increase across cycles.³⁷ Serious treatment-emergent AEs occurred in 16.2% of patients in the NEPA group (two were treatment-related) and 18.3% of patients in the aprepitant plus palonosetron group. GERSC was generally safe in patients receiving up to four cycles of MEC or HEC.¹⁰¹ No treatment-related serious AEs were observed. Most ISRs were mild, and those of moderate severity occurred in less than 3% of patients. ISRs included bruising (GERSC 500 mg, 29.7%), nodules (GERSC 500 mg, 17.5%), erythema (GERSC 500 mg, 11.8%), pain (GERSC 500 mg, 7.2%), and bleeding (GERSC 500 mg, 6.6%).¹⁰¹

Safety of 5HT₃ RAs in multiday chemotherapy

In a Phase III trial of GTDS in patients receiving multiday chemotherapy, the most common AE was constipation, occurring in 7% of patients,⁸⁰ and no QTc prolongation occurred with GTDS. Multiple doses of palonosetron 0.25 mg IV administered with dexamethasone were well tolerated in patients with multiple myeloma receiving multiday melphalan and hematopoietic stem-cell transplantation, and no serious drug-related AEs were reported.¹⁰⁵ In patients receiving up to six cycles of cisplatin, a combination of palonosetron 0.25 mg IV, aprepitant 125 mg PO, and dexamethasone 20 mg IV on day 1 of chemotherapy was well tolerated.¹⁰³

5HT₃ RAs for radiotherapy-induced NV and chemoradiation-induced NV

In addition to chemotherapy, other causes of NV include radiotherapy and concomitant chemotherapy and radiotherapy. Among patients receiving radiotherapy, 50%–80% may experience radiotherapy-induced NV (RINV), depending

on the site of irradiation, dose, fractionation schedule, and patient-related risk factors.¹²⁸ 5HT₃ RAs have been widely used for RINV prophylaxis,¹²⁸ and NCCN guidelines recommend pretreatment with oral granisetron or oral ondansetron, with or without oral dexamethasone, for each day of upper-abdomen, localized, or total-body irradiation.⁷

Despite widespread use of chemoradiation to treat gynecologic and other cancers, prophylactic antiemetic regimens for RINV and chemoradiation-induced NV (CRINV) are relatively underexplored.¹²⁹ The standard of care for women with cervical cancer involves weekly cisplatin-based HEC and concomitant fractionated radiotherapy, resulting in increased CINV risk in these patients, due to their young age, female sex, and the high emetogenicity of cisplatin.¹²⁹ In a Phase II study in 48 women receiving concomitant radiotherapy and cisplatin therapy for gynecologic cancers, prophylaxis with palonosetron 0.25 mg IV once on day 1 and prednisolone 100 mg once on day 1 followed by 50 mg twice on day 2, 25 mg twice on day 3, and 25 mg once on day 4 was insufficient for emesis control.¹³⁰ The primary end point, cumulative probability of patients completing five cycles of chemoradiation without emesis, was 57%.¹³⁰ A recent Phase III study in 246 women with cervical cancer receiving fractionated radiotherapy and weekly cisplatin for 5 weeks compared fosaprepitant 150 mg IV versus placebo, each combined with palonosetron 0.25 mg IV and dexamethasone 16 mg PO, for the control of CRINV.¹³¹ All patients received dexamethasone 8 mg PO twice on day 2, 4 mg PO twice on day 3, and 4 mg once on day 4. This was the first study to investigate the efficacy of a three-drug regimen in CRINV prevention. A greater proportion of patients receiving the fosaprepitant three-drug regimen did not experience emesis at 5 weeks (65.7% vs 48.7%), with a lower cumulative risk of emesis in these patients ($P=0.008$). These results represent a significant advance in CRINV management.

Conclusion

With the recent addition of new formulations of 5HT₃ RAs, health-care providers have a variety of agents to choose from. However, these agents have important differences in efficacy and safety, and the appropriate antiemetic regimen must be selected carefully, considering both chemotherapy regimen and schedule and patient-related risk factors.

For patients receiving single-day HEC, a three-drug antiemetic regimen is recommended, and the 5HT₃ RA included in this regimen may influence the combination's efficacy in preventing CINV. Ideally, the 5HT₃ RA in combination with an NK₁ RA and a corticosteroid should prevent CINV across both acute and delayed phases following HEC. Based

on clinical experience, first-generation 5HT₃ RAs such as ondansetron, older formulations of granisetron, and dolasetron IV (no longer approved in the USA to prevent CINV, because of potential cardiac effects) are considered similar in efficacy for preventing acute CINV following MEC or HEC, but considered inadequate for preventing delayed CINV following HEC.¹¹ Recent results with GERSC, the ER polymer formulation of granisetron using novel Biochronomer technology, change this view.⁵⁴ Two large Phase III trials in 2,370 patients have demonstrated that a single dose of GERSC is effective in preventing CINV following MEC and HEC regimens.^{54,59,86} GERSC was noninferior to the standard of care, palonosetron, in preventing CINV in the acute and delayed phases following MEC and in the acute phase following HEC, and numerically superior to palonosetron in preventing delayed CINV following HEC.⁸⁶ GERSC was also superior to ondansetron (when both agents were administered in the guideline-recommended three-drug regimen) in preventing delayed CINV following HEC.⁵⁴ In light of the need for better therapies to manage delayed CINV following HEC, GERSC provides a new and effective option. Furthermore, GERSC efficacy has been maintained over successive cycles of MEC or HEC.¹⁰¹ Therefore, GERSC is a convenient and effective SC option for acute and delayed CINV prevention following MEC or HEC administered over single or multiple cycles. In the USA, GERSC is indicated for use in combination with other antiemetics for the prevention of acute and delayed NV associated with initial and repeat courses of MEC and AC combination-chemotherapy regimens.

Another recent formulation, NEPA (fixed-dose netupitant and palonosetron), in combination with dexamethasone, has shown superiority to palonosetron plus dexamethasone in controlling CINV following MEC in acute, delayed, and overall phases and was effective over multiple cycles of MEC or HEC.^{37,45} As such, NEPA is an additional oral antiemetic option for patients receiving MEC or HEC.

Historically, CINV-prevention trials have typically used CR as the primary end point and focused on emesis control in both the acute and delayed phases of CINV, but delayed nausea, especially following HEC, continues to be inadequately controlled. The subjectivity in measuring nausea and the lack of understanding of its underlying pathophysiology have hindered the study of nausea control and the development of effective agents to prevent nausea. The use of a stringent no-nausea end point in clinical trials and a better understanding of the underlying pathophysiology are likely to lead to improved nausea control. Given the efficacy of olanzapine in nausea control, its addition to the existing three-drug regimen

may improve nausea management and may be the next step in CINV-prevention regimens. The continued occurrence of CINV, despite the availability of effective antiemetic regimens and comprehensive clinical practice guidelines, suggests the need for greater adherence to guidelines and better understanding of patient characteristics and genetic differences. Future research on 5HT₃-RA pharmacogenetics may improve the understanding of variability in patient response to antiemetics.^{110,132}

Acknowledgments

Research support was provided by Heron Therapeutics Inc (Redwood City, CA, USA). Medical writing assistance was provided by Doyel Mitra, PhD, Yvonne E Yarker, PhD, and Joanna Sandilos Rega, PhD, of SciStrategy Communications (Conshohocken, PA, USA).

Disclosure

JG has served as a member of a speaker bureau or advisory committee for Heron Therapeutics. LS has acted in a consultant/advisory role for Eisai, Helsinn, Merck, and Tesaro, received research funding from Helsinn, and served as a member of a speaker bureau or advisory committee for Helsinn and Merck. NG has served as a member of a speaker bureau or advisory committee for Eisai, Heron, and Tesaro. The authors report no other conflicts of interest in this work.

References

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. *J Clin Oncol*. 2006;24(27):4472–4478.
2. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. *Drugs*. 2013;73(3):249–262.
3. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. *Support Care Cancer*. 2007;15(5):497–503.
4. Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. *Support Care Cancer*. 2011;19(6):843–851.
5. van Laar ES, Desai JM, Jatoti A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. *Support Care Cancer*. 2015;23(1):151–157.
6. Coates A, Abraham S, Kaye SB, et al. On the receiving end: patient perception of the side-effects of cancer chemotherapy. *Eur J Cancer Clin Oncol*. 1983;19(2):203–208.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: antiemesis – v2.2018. 2018. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed May 25, 2018.
8. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. *J Clin Oncol*. 1997;15(1):103–109.
9. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: state of the art. *Support Care Cancer*. 2011;19 Suppl 1:S43–S47.
10. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. *Support Care Cancer*. 2012;20(1):107–117.
11. Navari RM. 5-HT receptors as important mediators of nausea and vomiting due to chemotherapy. *Biochim Biophys Acta*. 2015;1848(10 Pt B):2738–2746.
12. Janelins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opin Pharmacother*. 2013;14(6):757–766.
13. Shih TY, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. *Cancer*. 2007;110(3):678–685.
14. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. *Support Care Cancer*. 2011;19(1):131–140.
15. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. *N Engl J Med*. 2016;375(2):134–142.
16. Navari RM. *Management of Chemotherapy-Induced Nausea and Vomiting: New Agents and New Uses of Current Agents*. Basel, Heidelberg: Springer; 2016.
17. Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. *Support Care Cancer*. 2017;25(1):277–288.
18. Roila F, Warr D, Hesketh PJ, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. *Support Care Cancer*. 2017;25(1):289–294.
19. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2017;35(28):3240–3261.
20. Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. *J Oncol Pract*. 2014;10(1):68–74.
21. Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). *Ann Oncol*. 2012;23(8):1986–1992.
22. Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH. Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. *Am Health Drug Benefits*. 2015;8(5):273–282.
23. Kraut L, Fauser AA. Anti-emetics for cancer chemotherapy-induced emesis: potential of alternative delivery systems. *Drugs*. 2001;61(11):1553–1562.
24. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. *J Natl Cancer Inst*. 1991;83(9):613–620.
25. Kytril (granisetron) injection, for intravenous use [prescribing information]. San Francisco: Genentech; 2011.
26. van Wijngaarden I, Tulp MT, Soudijn W. The concept of selectivity in 5-HT receptor research. *Eur J Pharmacol*. 1990;188(6):301–312.
27. Anzemet tablets (dolasetron mesylate) [prescribing information]. Bridgewater (NJ): Sanofi-Aventis; 2013.

28. Kytril (granisetron hydrochloride) tablets, oral solution [prescribing information]. Nutley (NJ): Roche Laboratories; 2010.
29. Sustol (granisetron) extended-release injection, for subcutaneous use [prescribing information]. Redwood (CA): Heron Therapeutics; 2016.
30. Gabrail N, Yanagihara R, Spaczyński M, et al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two phase II trials. *Cancer Manag Res*. 2015;7:83–92.
31. Sancuso (granisetron transdermal system) [prescribing information]. Bridgewater (NJ): ProStrakan; 2015.
32. Zofran (ondansetron hydrochloride) injection for intravenous use [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2014.
33. Zofran (ondansetron hydrochloride) tablets [prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2016.
34. Aloxi (palonosetron HCl) injection for intravenous use [prescribing information]. Woodcliff Lake (NJ): Eisai; 2015.
35. Smith HS, Cox LR, Smith EJ. 5-HT₃ receptor antagonists for the treatment of nausea/vomiting. *Ann Palliat Med*. 2012;1(2):115–120.
36. Akynzeo (netupitant and palonosetron) capsules for oral use [prescribing information]. Woodcliff Lake (NJ): Eisai; 2016.
37. Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. *Ann Oncol*. 2014;25(7):1333–1339.
38. Tsukahara K, Nakamura K, Motohashi R, et al. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas. *Acta Otolaryngol*. 2014;134(11):1198–1204.
39. Vidall C, Fernandez-Ortega P, Cortinovis D, Jahn P, Amlani B, Scotte F. Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey. *Support Care Cancer*. 2015;23(11):3297–3305.
40. Eglen RM, Lee CH, Smith WL, et al. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT₃ receptor antagonist, in vivo. *Br J Pharmacol*. 1995;114(4):860–866.
41. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT₃ receptor internalization and causes prolonged inhibition of receptor function. *Eur J Pharmacol*. 2010;626(2–3):193–199.
42. Wong EH, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT₃ receptors, in vitro. *Br J Pharmacol*. 1995;114(4):851–859.
43. Stoltz R, Parisi S, Shah A, Maccicchi A. Pharmacokinetics, metabolism and excretion of intravenous [¹⁴C]-palonosetron in healthy human volunteers. *Biopharm Drug Dispos*. 2004;25(8):329–337.
44. Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. *Ann Oncol*. 2014;25(7):1340–1346.
45. Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. *Ann Oncol*. 2014;25(7):1328–1333.
46. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. *Lancet Oncol*. 2015;16(9):1079–1089.
47. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. *Lancet Oncol*. 2015;16(9):1071–1078.
48. Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H. A review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. *Biomed Res Int*. 2015;2015:651879.
49. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. *Ann Oncol*. 2006;17(9):1441–1449.
50. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. *Lancet Oncol*. 2009;10(2):115–124.
51. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. *Support Care Cancer*. 2013;21(6):1655–1663.
52. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol – EASE. *J Clin Oncol*. 2011;29(11):1495–1501.
53. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. *J Support Oncol*. 2011;9(5):188–195.
54. Schnadig ID, Agajanian R, Dakhil SR, et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. *Future Oncol*. 2016;12(12):1469–1481.
55. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 study group. *J Clin Oncol*. 2003;21(22):4112–4119.
56. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. *Cancer*. 2003;97(12):3090–3098.
57. Saito H, Yoshizawa H, Yoshimori K, et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. *Ann Oncol*. 2013;24(4):1067–1073.
58. Hu Z, Cheng Y, Zhang H, et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. *Support Care Cancer*. 2014;22(4):979–987.
59. Raftopoulos H, Cooper W, O’Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. *Support Care Cancer*. 2015;23(3):723–732.
60. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: results of a prospective randomized trial. *Cancer*. 1994;74(7):1945–1952.
61. Matsumoto K, Takahashi M, Sato K, et al. Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. *J Clin Oncol*. 2015;33 (15 Suppl):9598.
62. Saito M, Uomori T, Miura K, et al. Comparison between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy in breast cancer patients: according to recent multi-institutional double-blind randomized study. *Support Care Cancer*. 2017;25 Suppl 2:PS054.

63. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist: results of a phase III, single-dose trial versus dolasetron. *Cancer*. 2003;98(11):2473–2482.
64. Gralla R, Lichinitser M, van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. *Ann Oncol*. 2003;14(10):1570–1577.
65. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. *J Clin Oncol*. 2005;23(12):2822–2830.
66. Grunberg SM, Dugan M, Muss H, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. *Support Care Cancer*. 2009;17(5):589–594.
67. Aapro M, Fabi A, Nole F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. *Ann Oncol*. 2010;21(5):1083–1088.
68. Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. *Support Care Cancer*. 2010;18(4):423–431.
69. Celio L, Frustaci S, Denaro A, et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. *Support Care Cancer*. 2011;19(8):1217–1225.
70. Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. *Support Care Cancer*. 2013;21(5):1453–1460.
71. Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. *J Clin Oncol*. 2014;32(30):3413–3420.
72. Komatsu Y, Okita K, Yuki S, et al. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. *Cancer Sci*. 2015;106(7):891–895.
73. Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. *Eur J Cancer*. 2015;51(10):1274–1282.
74. US Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). 2010. Available from: <https://www.fda.gov/Drugs/Drug-Safety/ucm237081.htm>. Accessed October 10, 2017.
75. Kolesar JM, Eickhoff J, Vermeulen LC. Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? *Am J Health Syst Pharm*. 2014;71(6):507–510.
76. Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting. *Am J Health Syst Pharm*. 2014;71(6):500–506.
77. Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT₃R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. *Support Care Cancer*. 2011;19(6):823–832.
78. Popovic M, Warr DG, Deangelis C, et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer*. 2014;22(6):1685–1697.
79. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. *J Oncol Pharm Pract*. 2009;15(4):223–231.
80. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. *Support Care Cancer*. 2011;19(10):1609–1617.
81. Seol YM, Kim HJ, Choi YJ, et al. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. *Support Care Cancer*. 2016;24(2):945–952.
82. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. *Eur J Pharm Biopharm*. 2006;64(1):1–8.
83. Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. *Cancer Manag Res*. 2013;5:179–185.
84. Ottoboni T, Gelder MS, O'Boyle E. Biochronomer technology and the development of APF530, a sustained release formulation of granisetron. *J Exp Pharmacol*. 2014;6:15–21.
85. Heller J, Barr J. Biochronomer technology. *Expert Opin Drug Deliv*. 2005;2(1):169–183.
86. Raftopoulos H, Boccia R, Cooper W, O'Boyle E, Gralla RJ. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. *Future Oncol*. 2015;11(18):2541–2551.
87. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. *Eur J Cancer*. 1990;26 Suppl 1:S23–S27.
88. de Mulder PH, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, crossover study. *Ann Intern Med*. 1990;113(11):834–840.
89. Grunberg SM, Stevenson LL, Russell CA, McDermid JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. *J Clin Oncol*. 1989;7(8):1137–1141.
90. Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. *J Clin Oncol*. 1996;14(8):2242–2249.
91. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. *J Clin Oncol*. 2005;23(6):1289–1294.
92. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis: moderately emetogenic chemotherapy. *Support Care Cancer*. 2005;13(2):104–108.
93. Gralla RJ, de Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT₃ antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. *Cancer*. 2005;104(4):864–868.
94. Hesketh PJ. Comparative review of 5-HT₃ receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. *Cancer Invest*. 2000;18(2):163–173.
95. Schnadig ID, Agajanian R, Dakhil SR, et al. Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. *Cancer Manag Res*. 2017;9:179–187.

96. Schwartzberg L, Mosier M, Geller RB, Klepper MJ, Schnadig I, Vogelzang NJ. APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis. *J Community Support Oncol*. 2017;15(2):82–88.
97. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2011;29(31):4189–4198.
98. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. *Br J Cancer*. 2006;94(7):1011–1015.
99. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. *Support Care Cancer*. 2010;18(7):869–876.
100. Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. *Support Care Cancer*. 2012;20(7):1507–1514.
101. Boccia R, Cooper W, O'Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. *J Community Support Oncol*. 2015;13(2):38–46.
102. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT₃ receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study. *J Clin Oncol*. 2012;30(32):3998–4003.
103. Longo F, Mansueto G, Lapadula V, et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy. *Int J Clin Pract*. 2012;66(8):753–757.
104. Feinberg B, Gilmore J, Haislip S, et al. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. *Support Care Cancer*. 2012;20(3):615–623.
105. Giralt SA, Mangan KF, Maziarz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. *Ann Oncol*. 2011;22(4):939–946.
106. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfeleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. *Eur J Cancer*. 1992;28(2–3):450–457.
107. Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. *Support Care Cancer*. 2011;19(6):807–813.
108. Takeshima N, Matoda M, Abe M, et al. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. *Support Care Cancer*. 2014;22(11):2891–2898.
109. Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. *Ann Oncol*. 2017;28(6):1260–1267.
110. Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? *Curr Oncol Rep*. 2013;15(3):276–285.
111. de Wit R, Aapro M, Blower PR. Is there a pharmacological basis for differences in 5-HT₃-receptor antagonist efficacy in refractory patients? *Cancer Chemother Pharmacol*. 2005;56(3):231–238.
112. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. *Drug Metab Dispos*. 1995;23(11):1225–1230.
113. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT₃ antagonists. *Drug Metab Dispos*. 1996;24(5):602–609.
114. Hassan BA, Yusoff ZB. Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. *Asian Pac J Cancer Prev*. 2011;12(1):185–191.
115. Andersen RL, Johnson DJ, Patel JN. Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. *Pharmacogenomics*. 2016;17(4):417–434.
116. Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M. CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. *Curr Drug Metab*. 2005;6(5):469–480.
117. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. *J Clin Oncol*. 2002;20(12):2805–2811.
118. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. *Oncologist*. 2004;9(6):673–686.
119. de Leon A. Palonosetron (Aloxi): a second-generation 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting. *Proc (Bayl Univ Med Cent)*. 2006;19(4):413–416.
120. Morrison D, Anderson A, Slama M, et al. Phase 1 bioavailability study comparing 2 different subcutaneous routes of administration for APF530. *Support Care Cancer*. 2015;23 Suppl:11–16-P.
121. Boyer EW, Shannon M. The serotonin syndrome. *N Engl J Med*. 2005;352(11):1112–1120.
122. US Food and Drug Administration. FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). 2012. Available from: <http://www.fda.gov/Drugs/Drug-Safety/ucm310190.htm>. Accessed March 2, 2017.
123. Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. *Support Care Cancer*. 2015;24(2):621–627.
124. Spinelli T, Moresino C, Baumann S, Timmer W, Schultz A. Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial. *Springerplus*. 2014;3:389.
125. Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. *Clin Cancer Res*. 2012;18(10):2913–2921.
126. Mason JW, Moon TE, O'Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. *Cancer Manag Res*. 2014;6:181–190.
127. Brygger L, Herrstedt J. 5-Hydroxytryptamine 3 receptor antagonists and cardiac side effects. *Expert Opin Drug Saf*. 2014;13(10):1407–1422.
128. Feyer P, Jahn F, Jordan K. Prophylactic management of radiation-induced nausea and vomiting. *Biomed Res Int*. 2015;2015:893013.
129. Schwartzberg L. Progress in chemoradiotherapy-induced nausea and vomiting. *Lancet Oncol*. 2016;17(4):412–413.
130. Ruhlmann CH, Belli C, Dahl T, Herrstedt J. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin: a phase II study. *Support Care Cancer*. 2013;21(12):3425–3431.
131. Ruhlmann CH, Christensen TB, Dohn LH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. *Lancet Oncol*. 2016;17(4):509–518.
132. Sugino S, Janicki PK. Pharmacogenetics of chemotherapy-induced nausea and vomiting. *Pharmacogenomics*. 2015;16(2):149–160.
133. Tesaro. Tesaro announces fourth-quarter and full-year 2017 operating results. 2018. Available from: <http://ir.tesarobio.com/news-releases/news-release-details/tesaro-announces-fourth-quarter-and-full-year-2017-operating>. Accessed March 5, 2018.

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes

a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>